EP1727550A1 - Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein - Google Patents

Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein

Info

Publication number
EP1727550A1
EP1727550A1 EP05718061A EP05718061A EP1727550A1 EP 1727550 A1 EP1727550 A1 EP 1727550A1 EP 05718061 A EP05718061 A EP 05718061A EP 05718061 A EP05718061 A EP 05718061A EP 1727550 A1 EP1727550 A1 EP 1727550A1
Authority
EP
European Patent Office
Prior art keywords
phenyl
dihydro
benzo
oxo
diazepin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05718061A
Other languages
German (de)
French (fr)
Other versions
EP1727550B1 (en
Inventor
Kenneth Arrow Therapeutics Limited POWELL
Richard Arrow Therapeutics Limited KELSEY
Malcolm Arrow Therapeutics Limited CARTER
Dagmar Arrow Therapeutics Limited ALBER
Lara Arrow Therapeutics Limited WILSON
Elisa Arrow Therapeutics Limited HENDERSON
Phil Arrow Therapeutics Limited CHAMBERS
Debra Arrow Therapeutics Limited TAYLOR
Stan Arrow Therapeutics Limited TYMS
Verity Arrow Therapeutics Limited DOWDELL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrow Therapeutics Ltd
Original Assignee
Arrow Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrow Therapeutics Ltd filed Critical Arrow Therapeutics Ltd
Priority to PL05718061T priority Critical patent/PL1727550T3/en
Publication of EP1727550A1 publication Critical patent/EP1727550A1/en
Application granted granted Critical
Publication of EP1727550B1 publication Critical patent/EP1727550B1/en
Priority to CY20091101108T priority patent/CY1109523T1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms

Definitions

  • the present invention relates to a series of anti-viral benzodiazepine derivatives.
  • a series of benzodiazepine derivatives which interact with an inhibitor ofthe RSV fusion protein to provide an additive or synergistic therapeutic effect in treating or preventing an RSV infection.
  • Respiratory Syncytial Virus (RSV) is a major cause of respiratory illness in patients of all ages. In adults, it tends to cause mild cold symptoms. In school-aged children, it can cause a cold and bronchial cough. In infants and toddlers it can cause bronchiolitis (inflammation ofthe smaller airways ofthe lungs) or pneumonia.
  • Small compounds which inhibit RSV replication by inhibiting the fusion (F) protein of RSV block the entry ofthe virus into the host cell and the exit from the host cell via syncytia formation. While these compounds have been shown to have high potency, RSV rapidly develops resistance to these compounds through mutations in the F protein (Morton, C.J. et al, 2003Nirology 311, 275-288).
  • PCT/GB03/04050 filed on 20 September 2003 discloses a series of benzodiazepine derivatives which inhibit RSV replication. Serial passaging experiments have indicated that resistance to these inhibitors is slow to develop and sequencing of resistant mutants did not reveal any significant changes in the F protein.
  • the present invention therefore provides, in a first embodiment, a pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and (a) an inhibitor ofthe RSV fusion protein; and: (b) a benzodiazepine derivative capable of inhibiting RSV replication.
  • a pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and (a) an inhibitor ofthe RSV fusion protein; and: (b) a benzodiazepine derivative capable of inhibiting RSV replication.
  • components (a) and (b) have at least an additive effect.
  • the concepts of synergism and additivity are, of course, well known in the field of pharmacology. It is thus well established that a therapeutically useful additive combination is one in which the effect of the combination is greater than the larger ofthe effects produced by each ofthe components at the same concentrations as in the mixture.
  • a given formulation containing x wt% of component (a) and y wt% of component (b) has an activity which is at least as great as the activity of a formulation containing, as sole active ingredient, either x wt% component (a) or y wt% component (b).
  • the active ingredients are typically operating via different physiological pathways.
  • component (a) and component (b) are believed to be inhibiting separate RSV proteins.
  • An additive combination is therapeutically useful because it can achieve a therapeutically useful effect using lower concentrations of each active component. This enables the side-effects of the medication to be minimised.
  • an inhibitor ofthe RSV fusion protein can be identified by an assay comprising: (a) labelling RSV with octadecyl rhodamine dye (Rl 8); (b) pre-incubating the labelled virus with Hep-2 cells seeded in a 6-well plate at 1 hour for 4°C; (c) removing unattached virus; (d) adding the candidate fusion protein inhibitor; (e) incubating the 6-well plates at 37°C for 1 hour; and (f) determining any increase in fluorescence, typically using a fluorescence microscope.
  • Rl 8 octadecyl rhodamine dye
  • any increase in fluorescence signifies a fusion event.
  • 100% inhibition is achieved.
  • a control of growth medium and solvent e.g., growth medium with 10% fetal bovine serum and DMSO
  • 0% inhibition is achieved.
  • the % inhibition achieved with the candidate fusion protein inhibitor can be determined by quantitative assessment ofthe fluorescence in step (f).
  • component (a) is typically a compound which achieves at least 10%, more typically at least 30%, preferably at least 50% and most preferably at least 75%, inhibition ofthe RSV fusion protein as determined by the above assay.
  • component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,
  • X is a direct link or C ⁇ - 6 alkyl; said C ⁇ . 6 alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCORi or S(O)n-C ⁇ .
  • Z is CR ⁇ R 7 , where R ⁇ and R 7 are independently H, or straight, branched or cyclic C ⁇ -6 alkyl; n is 1-2; Ri is CONl ⁇ Rs, CC ⁇ , or Ci- 6 alkyl, said C ⁇ . 6 alkyl can be optionally substituted with OI ⁇ or NRsRg; Rg.
  • R are each independently H, C ⁇ - 6 alkyl, SO 2 R 5 , CO2 1 or COR 4 ;
  • Rio and Rn are each independently selected from the group consisting of H, C ⁇ -6 alkyl, C 3 - 6 cycloalkyl, CO 2 R 4 , COR, and SO 2 R 4 ;
  • - R 3 is selected from the group consisting of (1) CO 2 R 9 ; (2) C ⁇ . 6 alkyl optionally substituted with CN, OR» or NR ⁇ R 7 ; and (3) C 2 . 6 alkenyl substituted with CN;
  • Q is a member selected from the group consisting of
  • A is C or N, optionally substituted with H, halogen, - 6 alkyl, C 2 - 6 alkenyl, cyano-Ci- 6 alkyl, aryl, benzoaminocarbonyl, hydroxybenzyl, SO 2 NR 4 R 5 or C 3 - 6 cycloalkyl.
  • A is carbon, it may also be optionally substituted by O or S via a double bond;
  • Ri, R 2 and R are hydrogen, and the other is hydrogen or -C(NH)-NH 2 .
  • all of R h R 2 and R 3 are hydrogen.
  • either -X-Y is H, or X is a C ⁇ -C 6 alkyl ene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R".
  • Z is -CH 2 -.
  • Q is a moiety
  • B is -CH- or -N-, A . is -C(O)- or -NH- and A 2 is -CH 2 -, -CHR'- or -NR.”-, wherein R ; is a halogen atom and R 7 represents a hydrogen atom or a C ⁇ -C 4 alkyl, C 2 -C 4 alkenyl, C 3 -C 6 cycloalkyl, -SO 2 -(C,-C 6 alkyl), -SO 2 -N(C ⁇ -C 6 alkyl) 2 or -(CO-NH) a -(C ⁇ -C 4 alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.
  • Particularly preferred compounds of the invention are compounds of formula (la) and pharmaceutically acceptable salts thereof
  • each X is the same or different and is CH or N; - each R ⁇ is the same or different and is C ⁇ .
  • 6 alkyl, halogen, hydroxy, phenyl or (CH 2 ) m NH 2 ; n is 1 or 2; R 2 is C i - 6 alkoxy or C ⁇ . 6 alkoxy-phenyl ; R 3 is C ⁇ - 6 alkyl; - L 2 is -CH 2 - or -NH-; Y is C ⁇ - 6 alkyl or C ⁇ .
  • Li is -CH 2 -.
  • L 2 is -NH-.
  • Ri is methyl or hydroxy.
  • n is 2.
  • each Ri is different.
  • Y is C ⁇ -C 4 alkyl.
  • Z is -NH 2 .
  • Other preferred compounds of formula (II) are compounds of formula
  • Component (a) can also be a compound of formula (III), or a pharmaceutically acceptable salt thereof,
  • Ri is H, hydroxyl, alkyl, halogen, nitro or alkoxy; said alkoxy being optionally monosubstituted with carboxy, amino, monoalkylamino, dialkylamino or acetoamino;
  • R 2 is pyrazolyl, triazolyl or tetrazolyl and optionally substituted by amino or alkyl.
  • Component (a) can also be a compound of formula (IV), or a pharmaceutically acceptable salt thereof.
  • the compound of formula (IV) is 4,4'-Bis-(4,6-bis- ⁇ 3-[bis-(2-carbamoyl-ethyl)- sulfamoyl]-phenylamino ⁇ -[l,3,5]triazin-2-ylamino)-biphenyl-2,2'-disulfonic acid.
  • component (a) is: l-Cyclopropyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- imidazo[4,5-c]pyridin-2-one ⁇ 2-[2-(l,2-Dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l-yl]]ethyl ⁇ -diethyl- amine ⁇ 2-[2-(3-Iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]-ethyl ⁇ -dimethyl- amine l-Isopropenyl-3-[l-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- benzoimidazol-2-one 1 -(4-Hydroxy-benz
  • the composition contains an RSV fusion inhibitor, as described above, and a benzodiazepine identifiable as having anti-RSV activity by the method of Example 8.
  • component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,
  • R 1 represents C ⁇ . 6 alkyl, aryl or heteroaryl
  • R 2 represents hydrogen or C ⁇ - 6 alkyl
  • each R 3 is the same or different and represents halogen, hydroxy, C ⁇ - 6 alkyl, C ⁇ . 6 alkoxy, C ⁇ - 6 alkylthio, Ci-e haloalkyl, C ⁇ . 6 haloalkoxy, amino, mono(C ⁇ .
  • a C ⁇ - 6 alkyl group or moiety is a linear or branched alkyl group or moiety containing from 1 to 6 carbon atoms, such as a C ⁇ . 4 alkyl group or moiety.
  • Examples of C alkyl groups and moieties include methyl, ethyl, n-propyl, t-propyl, n-butyl, t-butyl and t-butyl.
  • the alkyl moieties may be the same or different.
  • a hydroxyalkyl group is typically a said alkyl group that is substituted by one or more hydroxy groups. Typically, it is substituted by one, two or three hydroxy groups. Preferably, it is substituted by a single hydroxy group.
  • Preferred hydroxyalkyl groups are (monohydroxy)ethyl groups.
  • an acyl group is a C 2 . acyl group, for example a group -CO-R, wherein R is a said - 6 alkyl group.
  • an aryl group is typically a C ⁇ -io aryl group such as phenyl or naphthyl. Phenyl is preferred.
  • An aryl group may be unsubstituted or substituted at any position. Typically, it carries 0, 1, 2 or 3 substituents. Suitable substitutents on an aryl group include halogen, C ⁇ - 6 alkyl, C 2 - 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ . 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ - 6 alkyl)carbamoyl, di(C ⁇ .
  • substituents on an aryl group include halogen, C ⁇ - 6 alkyl, C 2 - ⁇ acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ - 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ - 6 alkyl)carbamoyl, di(C ⁇ - 6 alkyl)carbamoyl, amino, mono(C ⁇ - 6 alkyl)amino, di(d.
  • each R' and R 1 ' is the same or different and represents hydrogen or C ⁇ - 6 alkyl.
  • Preferred substituents on an aryl group include halogen, C ⁇ . 6 alkyl, C 2 . 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ .
  • each R 1 and R 11 is the same or different and represents hydrogen or C alkyl.
  • substituents on an aryl group include halogen, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ .
  • substituents include fluorine, chlorine, bromine, iodine, C ⁇ - 4 alkyl, C 2 ⁇ acyl, hydroxy, C alkoxy, C M alkylthio, C M haloalkyl, C M haloalkoxy, amino, mono(CM alkyl)amino, di(CM alkyl)amino, nitro, -CO2R , -S(O) 2 R and -S(O) 2 NH 2 , wherein R' represents C ⁇ - 2 alkyl.
  • references to an aryl group include fused ring systems in which an aryl group is fused to a monocyclic carbocyclyl, heterocyclyl or heteroaryl group or to a fused group which is a monocyclic carbocyclyl, heterocyclyl or heteroaryl group which is fused to a phenyl ring.
  • said fused ring systems are systems in which an aryl group is fused to a monocyclic carbocyclyl, heterocyclyl or heteroaryl group.
  • Preferred such ring systems are those wherein an aryl group is fused to a fused group which is a monocyclic heterocyclyl or heteroaryl group or to a monocyclic carbocyclic group fused to a phenyl ring, in particular those wherein an aryl group is fused to a heterocyclyl or heteroaryl group.
  • fused ring systems are groups in which a phenyl ring is fused to a thienyl group or to a tetrahydrofuranyl group to form a benzothienyl or dihydrobenzofuranyl group.
  • fused rings are groups in which a phenyl ring is fused to a dioxanyl group, a pyrrolyl group or a 2,3-dihydroinden-l-one group to form a benzodioxinyl, indolyl or a 9H-fluoren-9-one group.
  • a carbocyclyl group is a non-aromatic saturated or unsaturated monocyclic hydrocarbon ring, typically having from 3 to 6 carbon atoms.
  • it is a saturated hydrocarbon ring (i.e. a cycloalkyl group) having from 3 to 6 carbon atoms.
  • Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. It is preferably cyclopentyl or cyclohexyl.
  • a cycloalkyl group may be unsubstituted or substituted at any position. Typically, it carries 0, 1, 2 or 3 substituents. Suitable substitutents on a carbocyclyl group include halogen, C ⁇ . 6 alkyl, C 2 . 7 acyl, hydroxy, C ⁇ . 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ - 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C].
  • Suitable substitutents on a carbocyclyl group include halogen, C ⁇ - 6 alkyl, C 2 - 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ - 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ - 6 alkyl)carbamoyl, di(C ⁇ . 6 alkyl)carbamoyl, amino, mono(C ⁇ alkyl)amino, di(C ⁇ .
  • Particularly preferred substituents include fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M haloalkyl, nitro and oxo.
  • Examples of particularly preferred substituents include fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M haloalkyl and nitro.
  • Further examples of particularly preferred substituents include fluorine, C M alkyl, C M alkoxy, C M haloalkyl and nitro.
  • a heterocyclyl group is a non-aromatic saturated or unsaturated carbocyclic ring typically having from 5 to 10 carbon atoms, in which one or more, for example 1, 2 or 3, ofthe carbon atoms is replaced by a heteroatom selected from N, O and S. Saturated heterocyclyl groups are preferred.
  • Examples include tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, dioxolanyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, dioxanyl, piperazinyl, morpholinyl, thiomorpholinyl and thioxanyl. Further examples include dithiolanyl, oxazolidinyl, tetrahydrothiopyranyl and dithianyl. Piperazinyl, piperidinyl and morpholinyl are preferred.
  • references to a heterocyclyl group include fused ring systems in which a heterocyclyl group is fused to a phenyl group.
  • Preferred such fused ring systems are those wherein a 5- to 6-membered heterocyclyl group is fused to a phenyl group.
  • An example of such a fused ring system is a group wherein a lH-imidazol-2(3H)-onyl group or a imidazolidin-2-onyl group is fused to a phenyl ring to form a lH-benzo[c/]imidazol-2(3H)- onyl group.
  • a heterocyclyl group is monocyclic.
  • a heterocyclic group may be unsubstituted or substituted at any position. Typically, it carries 0, 1 or 2 substituents. Suitable substitutents on a heterocyclyl group include halogen, C ⁇ - 6 alkyl, C 2 . 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ . 6 haloalkyl, C ⁇ - 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ -6 alkyl)carbamoyl, di(C ⁇ -6 alkyl)carbomyl, amino, mono(C ⁇ - 6 alkyl)amino, di(C ⁇ .
  • each R f and R 7 is the same or different and represents hydrogen or C ⁇ - 6 alkyl.
  • suitable substitutents on a heterocyclyl group include halogen, C ⁇ - 6 alkyl, C 2 - 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ . 6 haloalkyl, C ⁇ .
  • Preferred substituents on a heterocyclyl group include halogen, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ - 6 haloalkoxy, mono(C ⁇ . 6 alkyl)amino, di(C ⁇ . 6 alkyl)amino, nitro, cyano and oxo.
  • Examples of preferred substituents on a heterocyclyl group include halogen, C ⁇ . 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ - 6 haloalkoxy, mono(Ci. 6 alkyl)amino, di(C ⁇ .
  • substituents include fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M haloalkyl, nitro and oxo.
  • substituents include fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M haloalkyl and nitro.
  • substituents include fluorine, C M alkyl, C M alkoxy, CM haloalkyl and nitro.
  • a heterocyclyl group is unsubstituted or substituted by one or two C ⁇ - 2 alkyl groups.
  • a halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine, fluorine or bromine. It is more preferably chlorine or fluorine.
  • an alkoxy group is typically a said alkyl group attached to an oxygen atom.
  • An alkylthio group is typically a said alkyl group attached to a thio group.
  • a haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms.
  • Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX 3 and -OCX 3 wherein X is a said halogen atom, for example chlorine or fluorine.
  • Particularly preferred haloalkyl groups are -CF 3 and -CC1 3 .
  • Particularly preferred haloalkoxy groups are -OCF 3 and -OCCl 3 .
  • a heteroaryl group is typically a 5- to 10 membered aromatic ring, such as a 5- or 6-membered ring, containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from O, S and N.
  • Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, thiazolyl, imidazolyl and pyrazolyl groups. Further examples include oxazolyl and isothiazolyl.
  • Preferred heteroaryl groups are pyridyl, thienyl, oxazolyl, isoxazolyl, furanyl and pyrazolyl. Examples of preferred heteroaryl groups are pyridyl, thienyl, isoxazolyl and furanyl.
  • references to a heteroaryl groups include fused ring systems in which a heteroaryl group is fused to a phenyl group.
  • Preferred such fused ring systems are those wherein a 5- to 6-membered heteroaryl group is fused to a phenyl group.
  • Examples of such fused ring systems are benzofuranyl, benzothiophenyl, indolyl, benzimidazolyl, benzoxazolyl, quinolinyl, quinazolinyl and isoquinolinyl moieties.
  • a heterocyclyl group is monocyclic.
  • a heteroaryl group may be unsubstituted or substituted at any position.
  • Suitable substitutents on a heteroaryl group include halogen, C ⁇ - 6 alkyl, C 2 - 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ .
  • Suitable substitutents on a heteroaryl group include halogen, C ⁇ - 6 alkyl, C 2 . 7 acyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ . 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ . 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ - 6 alkyl)carbamoyl, di(C ⁇ . 6 alkyl)carbamoyl, amino, mono(C ⁇ .
  • references to a heteroaryl group include fused ring systems in which a heteroaryl group is fused to a monocyclic said aryl, carbocyclyl or heterocyclyl group, or to a further heteroaryl group.
  • Preferred such ring systems are those wherein a heteroaryl group is fused to an aryl group, for example a phenyl group.
  • An example of such a fused ring system is a group wherein a thienyl group is fused to a phenyl ring to form a benzothienyl group.
  • a further example of such a fused ring system is a group wherein a furanyl group is fused to a phenyl ring to form a benzofuranyl group.
  • R 1 in the formula (V) is an aryl or heteroaryl group it is typically unsubstituted or substituted by one, two or three substituents selected from halogen, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl or C ⁇ - 6 haloalkoxy.
  • it is unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M alkylthio, C M haloalkyl or C M haloalkoxy.
  • R 1 in the formula (V) is C ⁇ - 6 alkyl or aryl.
  • R 1 is C ⁇ . 2 alkyl or aryl.
  • R 1 is C ⁇ - 2 alkyl or phenyl.
  • R 1 is phenyl.
  • R 2 in the formula (V) is hydrogen or C alkyl.
  • R 2 is hydrogen.
  • R 3 in the formula (V) is halogen, hydroxy, C M alkyl, C M alkoxy, C M alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(CM alkyl)amino or di(C alkyl)amino.
  • R is fluorine, chlorine, bromine, C ⁇ . 2 alkyl, C ⁇ . 2 alkoxy, C ⁇ - 2 alkylthio, C ⁇ - 2 haloalkyl, C ⁇ . 2 haloalkoxy, amino, mono(C ⁇ . 2 alkyl)amino or di(C ⁇ - 2 alkyl)amino.
  • R 3 is methyl, trifluoromethyl, fluorine, chlorine or bromine. Most preferably, R 3 is methyl or chlorine. An example of a most preferred group is when R 3 is chlorine.
  • n in the formula (V) is 0, 1 or 2.
  • n is 0 or 1.
  • R 4 in the formula (V) is hydrogen or C ⁇ - 4 alkyl.
  • R 4 is hydrogen or Ci-2 alkyl. More preferably, R 4 is hydrogen or methyl.
  • R 4 is hydrogen.
  • R 5 in the formula (V) is a heterocyclyl group, it is typically attached via a carbon atom.
  • R 5 is C ⁇ - 6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C M alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(C M alkyl)-, heterocyclyl-(CM alkyl)-, aryl- C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR 6 .
  • R 5 groups are those wherein R 5 is Cue alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(C ⁇ - 4 alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)- or -XR 6 .
  • R 5 in the formula (V) is C M alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(C ⁇ - 2 alkyl)-, for example benzyl, heteroaryl-(C ⁇ - 2 alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR 6 .
  • R 5 groups are those wherein R 5 is C M alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(C ⁇ . 2 alkyl)-, for example benzyl, heteroaryl-(C ⁇ - 2 alkyl)- or -XR 6 .
  • R 5 in the formula (V) is C M alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- CH 2 -, furanyl-CH 2 -, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR 6 .
  • R 5 groups are those wherein R 5 is C M alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH 2 -, furanyl- CH 2 - or -XR 6 .
  • R 5 in the formula (V) is phenyl-CH 2 -, furanyl-CH 2 -, -C(O)-C(O)- thienyl or -XR 6 .
  • R 5 groups examples are those wherein R 5 is phenyl-CH2-, furanyl-CH 2 - or -XR 6 .
  • X in the formula (V) is -CO-, -S(O)- or -S(O) 2 -.
  • X is -CO- or
  • R 6 in the formula (V) is a group -NR'R ⁇ and either R or R includes an aryl, heteroaryl, carbocyclyl or heterocyclyl moiety it is typically unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ . 6 haloalkyl, C ⁇ . 6 haloalkoxy, nitro and cyano.
  • the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M alkylthio, C M haloalkyl, C M haloalkoxy and nitro.
  • substituents selected from fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M alkylthio, C M haloalkyl, C M haloalkoxy and nitro.
  • the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C ⁇ . 2 alkyl, Ci. 2 alkoxy, C ⁇ - 2 alkylthio, C ⁇ . 2 haloalkyl and nitro.
  • substituents selected from fluorine, chlorine, bromine, C ⁇ . 2 alkyl, Ci. 2 alkoxy, C ⁇ - 2 alkylthio, C ⁇ . 2 haloalkyl and nitro.
  • An example of more preferred substitution is when the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by a single fluoro, chloro, methyl, methoxy or nitro substituent.
  • R or R" is a heteroaryl or heterocyclyl group, it is attached via a carbon atom.
  • R' and R" in the group in the formula (V) are not both hydrogen.
  • each R' and R ⁇ is the same or different and represents hydrogen, C M alkyl, aryl, heteroaryl, carbocyclyl, aryl-(CM alkyl)- or heteroaryl-(CM alkyl)-.
  • Examples of typical R f and R" groups are those wherein each R' and R is the same or different and represents hydrogen, C M alkyl, phenyl, heteroaryl, for example thienyl, carbocyclyl, for example cyclohexyl or cyclopentyl, or phenyl-(CM alkyl)-.
  • R' and R 7/ groups are those wherein each R and R is the same or different and represents hydrogen, Ci. 4 alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH 2 )-.
  • each R' and R !/ is the same or different and represents hydrogen, C M alkyl, phenyl, phenyl-CH 2 -, cyclohexyl or cyclopentyl. More preferably, one of R f and R represents hydrogen.
  • one of R and R is hydrogen and the other is C M alkyl, phenyl, phenyl-CH 2 -, cyclohexyl or cyclopentyl.
  • one of R and R /f is hydrogen and the other is C M alkyl, phenyl, thienyl or phenyl-CH2-.
  • R 6 in the formula (V) is C ⁇ - 6 alkyl, hydroxy, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocycl yl-(CM alkyl)-, aryl -(CM hydroxyalkyl)-, heteroaryl-(C ⁇ .
  • R 6 in the formula (V) is C ⁇ - 6 alkyl, C ⁇ -6 alkoxy, C ⁇ - 6 alkylthio, aryl, for example phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl and indolyl, heteroaryl, for example thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl and benzofuranyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperazinyl, piperidinyl, morpholinyl and lH-benzo[c ]imidazol- 2(3H)-onyl, phenyl-(C ⁇ - 2 alkyl)-, phenyl-(C ⁇ - 2 alkyl)-O-,
  • R are as defined above.
  • preferred R 6 groups are those wherein R is C M alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example N-heterocyclyl, phenyl-(C ⁇ - 2 alkyl)-, for example benzyl, heteroaryl-(C ⁇ -2 alkyl)- or -NR'R' wherein R and R are as defined above.
  • R 6 in the formula (V) is C M alkyl, C M alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9 ⁇ -fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C ⁇ - 2 alkyl)-, phenyl-CH 2 -CH(OH)-, phenyl- CH(OH)-CH 2 -, phenyl-(C ⁇ - 2 alkyl)-O-, lH-benzo[ ⁇ imidazol-2(3H)-onyl or -NR'R" wherein R f and R f and R
  • R 6 groups are those wherein R 6 is C M alkyl, phenyl, thienyl, furanyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, isoxazolyl, piperidinyl, for example N-piperidinyl, morpholinyl, for example N-morpholinyl, piperazinyl, for example N-piperazinyl, or -NR'R wherein R and R" are as defined above.
  • Preferred compounds ofthe formula (V) are those in which: - R 1 is C ⁇ - 6 alkyl or aryl; R 2 is hydrogen or C alkyl; R 3 is halogen, hydroxy, C M alkyl, C M alkoxy, C M alkylthio, C M haloalkyl, CM haloalkoxy, amino, mono(C ⁇ - 4 alkyl)amino or di(C alkyl)amino or, preferably, R is fluorine, chlorine, bromine, C ⁇ .
  • R 4 is hydrogen or C M alkyl
  • R 5 is C ⁇ -6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(C M alkyl)-, carbocyclyl-(C M alkyl)-, heterocyclyl-(C M alkyl)-, aryl- C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR 6 ;
  • X is -CO-, -S(O)- or -S(O) 2 -; and
  • R 6 is C 1- 6 alkyl, hydroxy, C ⁇ .
  • Ci-6 haloalkoxy the aryl and heteroaryl moieties in the groups R 5 and R 6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C ⁇ . 6 alkyl, C 2 . 7 acyl, hydroxy, C ⁇ . 6 alkoxy, C ⁇ - 6 alkylthio, Ci-6 haloalkyl, C ⁇ - 6 haloalkoxy, nitro, cyano, carbamoyl, mono(C ⁇ . 6 alkyl)carbamoyl, di(C ⁇ - 6 alkyl)carbomyl, amino, mono(C ⁇ - 6 alkyl)amino, di(C ⁇ . 6 alkyl)amino,
  • each R' and R is the same or different and represents hydrogen or C ⁇ . 6 alkyl; the carbocyclyl and heterocyclyl moieties in the groups R 5 and R 6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C ⁇ - 6 alkyl, C 2 - acyl, hydroxy, Ci-6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, C ⁇ .
  • each R 1 and R / is the same or different and represents hydrogen or C ⁇ - 6 alkyl; and the alkyl moieties in the aryl-(C ⁇ - 4 alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(C ⁇ - 4 alkyl)- groups of R 6 being unsubstituted or substituted by one or two hydroxy substituents.
  • the aryl, heteroaryl and carbocyclyl moieties in the groups R' and R" are unsubstituted or substituted by 1 , 2 or 3 substituents selected from halogen, C ⁇ - 6 alkyl, C ⁇ - 6 alkoxy, C ⁇ - 6 alkylthio, C ⁇ - 6 haloalkyl, Ci-6 haloalkoxy, nitro and cyano.
  • R 1 is Ci-2 alkyl or phenyl
  • R 2 is hydrogen or C ⁇ - 4 alkyl
  • R 3 is methyl, trifluoromethyl, fluorine, chlorine or bromine
  • - n is 0 or 1
  • R 4 is hydrogen or C ⁇ - 2 alkyl
  • R 5 is C M alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(C ⁇ .
  • alkyl)- for example benzyl, heteroaryl-(C ⁇ - 2 alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR 6 , provided that when R 5 is heterocyclyl it is attached via a carbon atom; X is -CO-, -S(O)- or -S(O) 2 -; and R 6 is Ci-6 alkyl, C ⁇ - 6 alkoxy, C ⁇ .
  • aryl for example phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl and indolyl, heteroaryl, for example thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl and benzofuranyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperazinyl, piperidinyl, morpholinyl and lH-benzo[d]imidazol-2(3H)-onyl, phenyl-(C 1 - 2 alkyl)-, phenyl-(C ⁇ .
  • aryl for example phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl and in
  • each R' and R" is the same or different and represents hydrogen, C M alkyl, phenyl, heteroaryl, for example thienyl, carbocyclyl, for example cyclohexyl or cyclopentyl, or phenyl-(C ⁇ -- ⁇ alkyl)-, the phenyl moiety in the R 1 group being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, C M alkyl, C M alkoxy, C M alkylthio, C M haloalkyl or C M haloalkoxy; the aryl moieties in the groups R 5 and R 6 being unsubstituted or substituted by 1
  • R is phenyl or methyl; R 3 is methyl or chlorine; n is 0 or 1 ; R 4 is hydrogen or methyl; R 5 is phenyl-CH 2 -, furanyl-CH 2 -, thienyl-C(O)-C(O)- or -XR 6 ; X is -CO- or -S(O) 2 -; and R 6 is C alkyl, C M alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(C ⁇
  • each R and R is the same or different and represents hydrogen, C M alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(C ⁇ 2 )-, the phenyl moiety in the group R 1 being unsubstituted or substituted by a single fluorine, chlorine, C ⁇ - 2 alkyl, C ⁇ - 2 alkoxy, C ⁇ - 2 alkylthio, C1-2 haloalkyl or C 1.2 haloalkoxy substituent; the aryl moieties in the groups R 5 and R 6 being unsubstituted or substituted by 1 ,2 or
  • R 1 in the formula (Va) is phenyl, n is 0, R 4 is hydrogen and R 5 is -CO- phenyl or -CO-NH-phenyl, wherein the phenyl group in R 5 is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, C1-C2 alkyl, C1-C2 alkoxy, C1-C2 haloalkyl, -CO ⁇ R 7 or -S(O) 2 R / , wherein each R is the same or different and represents C ⁇ -C 2 alkyl.
  • preferred compounds of formula (V) containing only one chiral centre include an R enantiomer in substantially pure form, an S enantiomer in substantially pure form and enantiomeric mixtures which contain an excess of the R enantiomer or an excess ofthe S enantiomer.
  • the compounds ofthe formula (V) can, if desired, be used in the form of solvates.
  • a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
  • Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid.
  • Pharmaceutical acceptable bases include alkali metal (e.g. sodium or potassium) and alkaline earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines.
  • component (b) is: N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-acetamide; 1 , 1 -Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-propionamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-butyramide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin
  • the compounds of formulae (I), (II), (III) and (IV) are known compounds. They are disclosed, for example, in WO 00/195910, WO 00/004900, WO 03/053344, US-A-4324794 and WO 01/00612, and can be prepared by the processes set out in those documents. WO 00/195910, WO 00/004900, WO 03/053344, US-A-4324794 and WO 01/00612 are incorporated herein by reference. Any ofthe compounds disclosed as fusion protein inhibitors in those documents can be used in the present invention.
  • Compounds of formula (V) may be prepared by reacting glyoxylic acid (HCO- CO 2 H), benzotriazole and an appropriate benzyl carbamate at reflux in toluene, under Dean- Stark conditions giving the key protected amino acid of formula (II )
  • amino acid of formula (II 7 ) can then be reacted with a suitable chlorinating agent, such as oxalyl chloride, followed by reaction with a 2- aminobenzophenone of formula (HI 7 )
  • the compound of formula (IN 7 ) can then be subjected to ammonolysis followed by ring closure in acetic acid containing ammonium acetate to obtain the protected benzodiazepine of formula (V 7 )
  • the compound of formula (V 7 ) can then be deprotected using hydrogen bromide in acetic acid to yield the deprotected amine of formula (VI 7 ).
  • Compounds of formula (V), in which R 5 is XR 6 and X is -CO- can be prepared by reacting a compound of formula (VI 7 ), as defined above, with an acid anhydride in a suitable solvent, preferably pyridine at ambient temperature, or with an acid chloride in a suitable solvent in the presence of a base, preferably in THF at ambient temperature with triethylamine present.
  • the compounds can be produced by reaction of a compound of formula (VI 7 ) with an acid in a suitable solvent in the presence of a base and a coupling agent, preferably in THF at ambient temperature with triethylamine and O- benzotriazol-1-yl-N, N, N', N'-tetramethyluronium hexafluorophosphate (HBTU) present.
  • a base and a coupling agent preferably in THF at ambient temperature
  • HBTU O- benzotriazol-1-yl-N, N, N', N'-tetramethyluronium hexafluorophosphate
  • the acid chloride used is an amino carbonyl chloride
  • the compound of formula (V) is a tertiary urea.
  • R 6 is NH-R 7
  • such compounds may be prepared by the reaction of a compound of formula (VI 7 ) with an isocyanate. This reaction is preferably carried out in THF at ambient temperature.
  • the isocyanate may be prepared in situ from the relevant amine and phosgene, in the presence of a base, usually triethylamine, again in THF.
  • a base usually triethylamine, again in THF.
  • Compounds of formula (V), in which R 5 is -XR 6 and X is -S(O) 2 - may be prepared by the reaction of a compound of formula (VI 7 ) with a suitable sulfonyl chloride.
  • compounds of formula (V), in which R 5 is XR 6 and X is -S(O)- may be prepared by the reaction of a compound of formula (VI 7 ) with a suitable sulfinyl chloride
  • Compounds of formula (V) in which R 5 is not XR 6 may be prepared by known methods.
  • a compound of formula (VI 7 ) can be reacted with a compound of formula R 5 -L, wherein L is a leaving group such as a chlorine atom, a mesylate group or a triflate group.
  • L is a leaving group such as a chlorine atom, a mesylate group or a triflate group.
  • R 5 is aryl or heteroaryl
  • L can be -B(OH) and the reaction may take place in the presence of copper acetate.
  • Such boronic acid coupling reactions will, of course, be familiar to those of skill in the art.
  • Compounds wherein R 5 is aryl or heteroaryl may also be prepared by way of a Buchwald reaction or by reaction of a compound of formula (VI 7 ) with an appropriate fluoroaryl or fluoroheteroaryl compound.
  • R 5 is a heteroaryl group
  • a suitable chloroheteroaryl or bromoheteroaryl compound e.g., a suitable chloroheteroaryl or bromoheteroaryl compound.
  • Compounds wherein R 5 is a carbocyclyl group may also be prepared by known methods, for example a compound wherein R 5 is cyclohexyl may be prepared by the reaction of a compound of formula (VI 7 ) with cyclohexanone in the presence of a reducing agent.
  • Compounds of formula (V) in which the R 5 group is aryl-(C ⁇ - 6 alkyl)-, heteroaryl-(G- 6 alkyl)-, carbocyclyl-(C ⁇ -6 alkyl)-, heterocyclyl-(G-6 alkyl)- can also be prepared by the reaction of a compound of formula (VI 7 ) with an aldehyde in the presence of a reducing agent.
  • a compound of formula (VI 7 ) with an aldehyde in the presence of a reducing agent.
  • such reactions between compounds of formula (VI 7 ) and aldehydes are carried out in a mixture of dichloromethane and acetic acid in the presence of sodium (triacetoxy)borohydride at ambient temperature.
  • the starting materials of formula (II 7 ), (III 7 ), (VII 7 ), and (VIII 7 ) are known compounds, or may be prepared by analogy with known methods. Further synthetic manipulation ofthe thus obtained compounds of formula (V) may be carried out by conventional methods to achieve further compounds of formula (V).
  • the benzodiazepines of formula (V) can be salified by treatment with an appropriate acid or base.
  • the benzodiazepine ring system is formed by reaction initially with bromoacetyl bromide (or an equivalent reagent) followed by ring closure with ammonia. These reactions are carried out in a suitable solvent, such as dichloromethane, and at a suitable temperature which may range from -20 to 150°C.
  • a suitable solvent such as dichloromethane
  • the unsubstituted benzodiazepine is reacted with a base, and an alkylating agent. For instance sodium hydride in DMF followed by addition of 4-methoxy-benzyl chloride gives rise to the intermediate (2) shown below.
  • a base e.g. potassium tert-butoxide
  • a suitable solvent e.g. THF or DMF
  • isoamyl nitrite or an alternative similar reagent
  • This amine then undergoes a Dynamic Kinetic Resolution (DKR) procedure by which the racemic amine in the presence of a suitable optically active acid, and a suitable aldehyde gives rise to precipitation ofthe salt ofthe desired (S)-amine (4) in good yield and exceptionally high enantiomeric excess.
  • DKR Dynamic Kinetic Resolution
  • a suitable acid for this conversion can be e.g.
  • Camphorsulfonic acid, Boc-phenyl alanine or the like, and a suitable aldehyde may be a benzaldehyde such as 3,5- dichloro salicylaldehyde.
  • the optically amine thus formed may then be transformed into a desired derivative, such as an amide or urea.
  • the amide formations may be carried out using a suitable carboxylic acid and a coupling reagent, or a carbonyl chloride or other suitable reagent, and the ureas prepared using aeither a suitable isocyanate, or alternatively reaction with phosgene followed by a suitable amine. These derivatives thus formed may then have the protecting group removed.
  • This may be carried out in the presence of a Lewis Acid, such as aluminium chloride, boron trifluoride, titanium tetrachloride, or the like. These reactions are carried out in a suitable inert solvent, such as dichloromethane. Reaction temperatures may range from -20 to 150°C, but are typically carried out at room temperature or below.
  • a Lewis Acid such as aluminium chloride, boron trifluoride, titanium tetrachloride, or the like.
  • component (a) is 1- cyclopropyl-3-[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3-dihydro- imidazo[4,5-c]pyridin-2-one, 2-[2-(l,2-dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l- yl]]ethyl ⁇ -diethyl-amine, ⁇ 2-[2-(3-iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]- ethyl ⁇ -dimethyl-amine or a pharmaceutically acceptable salt thereof and component (b) is (S)-l-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]dia
  • the present invention also provides a pharmaceutical composition according to the invention, for use in the treatment ofthe human or animal body. Also provided is the use of (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative, in the manufacture of a medicament for use in treating or preventing an RSV infection.
  • the present invention also provides a method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative.
  • the amount of component (a) in the composition ofthe invention is from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, based on the total weight ofthe composition.
  • the amount of component (b) in the composition ofthe invention is from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, based on the total weight ofthe composition.
  • the total amount of components (a) and (b) in the composition ofthe invention is from 0.05 to 20 wt%, preferably from 0.5 to 10 wt%, more preferably from 2 to 7 wt%, for example about 5 wt%, based on the total weight ofthe composition.
  • RSV is prevalent among children younger than two years of age, adults suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency and the elderly. It is a particularly serious risk amongst children who suffer from chronic lung disease.
  • the said composition or medicament is typically for use in treating a patient who is a child under two years of age, patients with asthma, COPD or immunodeficiency the elderly or persons in long term care facilities.
  • said child suffers from chronic lung disease.
  • anti-RSV prophylaxis is recommended for infants born at 32 weeks of gestation or earlier, until they reach 6 months of age, the elderly, persons with immunedeficiency and those in long term care facilities.
  • the said composition or medicament is typically for use in preventing RSV infection in an infant less than 6 years of age, who was born after 32 weeks of gestation or less, the elderly, persons with immunosufficiency and those in long term care facilities.
  • RSV strains upon exposure to fusion inhibitors known in the art rapidly develop resistance. In order to minimize the risk of development of resistance to fusion inhibitors it is desirable to combine them with another inhibitor of RSV replication with a different mode of action.
  • the benzodiazepine derivatives disclosed above are the first class of compounds with a novel mode of action. Accordingly, the compositions ofthe invention are characterized by a very low resistance profile, which makes them particularly suitable for therapeutic and prophylactic applications.
  • the present invention also covers situations where components (a) and (b) are administered separately.
  • component (a) can be administered up to 24 hours before component (b).
  • component (b) can be administered up to 24 hours before component (a). More usually, when components (a) and (b) are administered separately, they are administered within 12 hours, preferably within 6 hours, of each other.
  • the present invention therefore also provides a product comprising (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative for separate, simultaneous or sequential use in the treatment ofthe human or animal body.
  • said product is for separate, simultaneous or sequential use in treating or preventing an RSV infection.
  • a said RSV fusion protein inhibitor in the manufacture of a medicament for use in treating or preventing an RSV infection by co-administration with a said benzodiazepine derivative.
  • the present invention also provides the use of a said benzodiazepine derivative in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a said RSV fusion protein inhibitor.
  • a first formulation is typically provided which contains from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, of a said RSV fusion protein inhibitor, based on the total weight ofthe formulation.
  • a second formulation is typically provided which contains from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example around 2.5 wt%, of a said benzodiazepine derivative, based on the total weight of the formulation.
  • the two formulations can be administered separately in any order.
  • the compositions and medicaments ofthe invention have an activity greater than the combined individual activities of compounds (a) and (b).
  • components (a) and (b) typically interact synergistically.
  • component (a) and component (b) are each present in an amount producing a synergistic therapeutic effect in treating or preventing an RSV infection.
  • the anti-RSV compositions ofthe invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories.
  • administration is by intravenous, intranasal or intrabronchial means.
  • formulations for treating or preventing RSV can advantageously be administered intranasally.
  • the present invention therefore also provides an inhaler or nebuliser containing a medicament which comprises (i) a composition of the invention comprising component (a) and component (b), as defined above, and (ii) a pharmaceutically acceptable carrier or diluent.
  • the anti-RSV compositions ofthe invention are typically formulated for administration with a pharmaceutically acceptable carrier or diluent.
  • solid oral forms may contain, together with the active compound(s), diluents, e.g.
  • lactose dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
  • binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone
  • disaggregating agents e.g.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • the anti-RSV compositions ofthe invention are solubilised in a carrier containing (a) a pharmaceutically acceptable oil selected from esterification or polyether products of glycerides with vegetable oil fatty acids of chain length C 8 -C ⁇ o and (b) a pharmaceutically acceptable surfactant selected from oleate and laurate esters of a polyalcohol copolymerized with ethylene oxide.
  • a pharmaceutically acceptable oil selected from esterification or polyether products of glycerides with vegetable oil fatty acids of chain length C 8 -C ⁇ o
  • a pharmaceutically acceptable surfactant selected from oleate and laurate esters of a polyalcohol copolymerized with ethylene oxide.
  • Particularly preferred carriers contain Labrafil as the oil and Tween 20 or Tween 80 as the surfactant.
  • the anti-RSV compositions ofthe invention also be suspended in PEG 400 for oral administration. A therapeutically effective amount of an anti-RSV composition ofthe invention is administered to a patient.
  • a typical dose is from about 0.001 to 50 mg, typically 0.5 to 30 mg, preferably 1 to 20 mg active ingredient per kg of body weight, according to the activity of the specific composition, the age, weight and conditions ofthe subject to be treated, the type and severity ofthe disease and the frequency and route of administration.
  • Preferably, daily dosage levels are from 5 mg to 2 g active ingredient.
  • the following Examples illustrate the invention. They do not however, limit the invention in any way. In this regard, it is important to understand that the particular assays used in the Examples section are designed only to provide an indication of antiviral activity. There are many assays available to determine the activity of given compounds against RSV, and a negative result in any one particular assay is therefore not determinative.
  • RSV enters the host cell via attachment to and fusion with the host cell membrane.
  • the effect of an inhibitor on the specific virus-cell fusion event can be qualitatively determined by using a fluorescence de-quenching system.
  • the design of this assay takes advantage ofthe fact that RSV binds to cells at 4°C and at 37°C but that fusion may only occur at concentrations above 18°C.
  • RSV labelled with octadecyl rhodamine dye (R18) is pre-incubated with Hep-2 cells seeded in a 6-well plate for 1 hour at 4°C to allow binding to occur. Unattached virus is removed by washing the cell monolayer.
  • the inhibitor is then added to the virus-cell complexes prior to transferring the plates to 37°C for 1 hour in order to induce fusion.
  • Virus-cell fusion can be observed directly under a fluorescence microscope. Fluorescence emission is quenched when 2 identical fluorophores are in close proximity. Upon fusion of the labelled virus with the cell membrane, the distance between fluorophores is increased due to dye spread and there is a decrease in quenching. This is observed as an increase in fluorescence intensity of R18. It therefore follows that inhibition of fusion would lead to a decrease in fluorescence of R18 compared to untreated control. Where the fluorescent yield of R18 in the presence of inhibitor is comparable to the untreated control this would suggest the inhibitor were not exerting its effects on the fusion protein.
  • the inner 60 wells of 96 well tissue culture plates are seeded with Hep-2 cells at 4xl0 4 cells/well for compound activity and toxicity studies in lOO ⁇ l of medium and incubated at 37°C overnight or until nearing confluency.
  • Cells are infected with 25 ⁇ l RSV, e.g. the RSS strain, previously titrated to give 80% cell kill.
  • 25 ⁇ M of test compound are added.
  • the final DMSO concentration is 0.5%.
  • Some 200 ⁇ l of sterile distilled water is added to the outer wells ofthe plate and incubated at 37°C for 6 days.
  • Some 0.25 ⁇ l/ml PMS are added to stock XTT solution, final cone. 25 ⁇ M PMS. Then 25 ⁇ l warmed XTT/PMS solution is added to each well and incubated for 1 hour at 37°C.
  • This assay was set up using all 96 wells of flat-bottomed 96-well plates. The outer wells were not subjected to any greater amount of evaporation than the inner wells during the 3 day assay period, (ie. No "edge effect" seen). Plates were set up one day before addition of virus and compounds. The assay then ran for 3 days with ELISA development taking place on the 4 th day.
  • GM Growth Medium
  • DMEM Dulbecco's MEM
  • Glutamax-1 Sodium Pyruvate, 1000 mg 1 glucose and pyridoxine (Invitrogen, catalogue number 21885-025) and supplemented with 10%FBS. (See Plate 1).
  • tissue culture the cells adhere to the tissue culture flask and were grown at 37°C, 5% CO2 until 90% confluent. Monolayers were washed with 20ml sterile PBS to remove serum and treated with 1ml trypsin to detach cells from the flask. Cells were suspended in a small known volume of growth media and counted using a haemocytometer. The cell suspension was made up to the desired concentration in growth medium and added to wells by multichannel pipette. Brief, gentle shaking encouraged the cells to disperse more evenly across the well.
  • Multiplicity of Infection plaque forming units per well (pfu/well) number of cells per well 25 ⁇ l (50 ⁇ l in Example 9c) of diluted virus was added to infected wells by multichannel pipette; 25 ⁇ l (50 ⁇ l in Example 9c) of Growth Medium was added to uninfected, cell control wells by multichannel pipette.
  • Compound Dilutions Compound "A” was titrated horizontally across the plate and Compound “B” was titrated vertically down the plate, creating a chequerboard. The 2 compounds were titrated at either Vi-log or doubling dilutions either across (horizontally) or down the plate (vertically) in the presence of virus. Each compound dilution was set up in duplicates or triplicates. For triplicates 3 identical plates were set up. Duplicates were set up as dublicate wells on the same plate. The dilution range covered concentrations from just above the compound IC50 to below the compound IC50 and included a O ⁇ M control for each compound.
  • Virus infected, untreated wells served as the virus control (VC); Uninfected, untreated wells serve as the cell control (CC).
  • CC cell control
  • the difference in absorbance between CC and VC wells constitutes the assay window.
  • Block solution was discarded down the sink and diluted primary antibody was added directly to wells (ie. no washing required).
  • RSV mouse monoclonal antibody NCL-RSV3 (Novocastra ) was diluted 1/400 in PBS/2% Marvel/0.05% Tween and 50 ⁇ l was added per well. Plates were incubated at 37°C in a shaking incubator for 90mins.
  • Antibody was discarded down the sink and plates were washed 6 times by immersion in PBS/0.05% Tween.
  • Substrate SigmaFast OPD
  • 1 urea tablet was prepared in advance by dissolving 1 urea tablet in 20mL water.
  • 1 OPD tablet was added to the urea solution just prior to use (NB.
  • OPD was light sensitive
  • vortexed to mix 50 ⁇ l of substrate was added per well.
  • reaction was stopped by addition of 25 ⁇ l/well of 20% sulphuric acid, once sufficient colour had developed but while cell control background was still low ( ⁇ 5 minutes).
  • the wells were emptied, washed in tap water and the monolayers stained with 50 ⁇ l/well of 2% crystal violet in 20% methanol/water for at least 1 hour. The wells were then washed and air-dried and the monolayers examined under the microscope for indications of cell toxicity.
  • the assay window was calculated by subtracting the meaned cell control (CC) from the meaned virus control (VC). For each compound, the meaned CC was subtracted from the meaned values for each concentration point. The % of control was then calculated for each concentration point as a percentage ofthe window. % of control was plotted against compound concentration. A straight line was fitted to the curve and the slope and intercept functions were used to calculate the IC50.
  • the IC50 for Compound “A” was calculated for each background concentration of Compound “B”. Similarly, the IC50 for Compound “B” was calculated for each background concentration of Compound “A”.
  • Compound B has an ELISA IC50 of 2 ⁇ M against the RSV RSS strain.
  • Compound A has an ELISA IC50 of 0.5 ⁇ M against the RSV RSS strain.
  • the IC50 of Compound B is reduced from 0.5 ⁇ M to at least 0.16 ⁇ M (3.2-fold decrease).
  • concentrations of Compound B below its IC50 (0.3, 0.1 ⁇ M) the IC50 of Compound A is reduced from 2 ⁇ M to at least 0.65 ⁇ M (3-fold decrease).
  • Compound B has an ELISA IC50 of 1.4 ⁇ M against the RSV RSS strain.
  • Compound A has an ELISA IC50 of 0.015 ⁇ M against the RSV RSS strain.
  • the IC50 of Compound A is reduced from 0.015 ⁇ M to at least 0.0007 ⁇ M (21.4-fold decrease).
  • concentrations of Compound A below its IC50 0.01, 0.003, 0.001, 0.0003 ⁇ M
  • the IC50 of compound B is reduced from 1.4 ⁇ M to at least 0.26 ⁇ M (5.4-fold decrease).
  • the IC50 of Compound B is reduced from 0.08 ⁇ M to at least 0.03 ⁇ M (2.66-fold decrease).
  • the IC50 of Compound A is reduced from l ⁇ M to at least 0.3 ⁇ M (3.33-fold decrease).
  • FIC Lowest IC50 Cud A C0MBINAT10N + Lowest IC50 Cpd B COMBINATION IC50 Cpd A ALONE IC50 Cpd B ⁇ 0

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor of the RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication is found to be highly active against RSV.

Description

PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN
The present invention relates to a series of anti-viral benzodiazepine derivatives. In particular, it relates to a series of benzodiazepine derivatives which interact with an inhibitor ofthe RSV fusion protein to provide an additive or synergistic therapeutic effect in treating or preventing an RSV infection. Respiratory Syncytial Virus (RSV) is a major cause of respiratory illness in patients of all ages. In adults, it tends to cause mild cold symptoms. In school-aged children, it can cause a cold and bronchial cough. In infants and toddlers it can cause bronchiolitis (inflammation ofthe smaller airways ofthe lungs) or pneumonia. It has also been found to be a frequent cause of middle ear infections (otitis media) in pre-school children. RSV infection in the first year of life has been implicated in the development of asthma during childhood. Current anti-RSV therapy involves the use of a monoclonal antibody to RSV, called palivizumab. Such use of palivizumab is a prophylactic, rather than therapeutic, treatment of RSV. However, although this antibody is often effective, it is expensive. Indeed, its expense means that it is unavailable for many people in need of anti-RSV therapy. There is therefore an urgent need for effective alternatives to existing anti-RSV therapy. Small compounds which inhibit RSV replication by inhibiting the fusion (F) protein of RSV block the entry ofthe virus into the host cell and the exit from the host cell via syncytia formation. While these compounds have been shown to have high potency, RSV rapidly develops resistance to these compounds through mutations in the F protein (Morton, C.J. et al, 2003Nirology 311, 275-288). PCT/GB03/04050 filed on 20 September 2003 discloses a series of benzodiazepine derivatives which inhibit RSV replication. Serial passaging experiments have indicated that resistance to these inhibitors is slow to develop and sequencing of resistant mutants did not reveal any significant changes in the F protein. It can therefore be assumed that these benzodiazepines have a common and novel mode of action, which does not involve inhibition ofthe F-protein. It has now surprisingly been shown that a combination of (a) an RSV fusion protein inhibitor and (b) an anti-RSV benzodiazepine is highly active against RSV. Components (a) and (b) are found to have at least an additive effect. Further, it is also a finding ofthe invention that the two components interact synergistically, to provide a combined effect that is greater than the sum ofthe effects ofthe individual components. The present invention therefore provides, in a first embodiment, a pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and (a) an inhibitor ofthe RSV fusion protein; and: (b) a benzodiazepine derivative capable of inhibiting RSV replication. It is a finding ofthe present invention that components (a) and (b) have at least an additive effect. The concepts of synergism and additivity are, of course, well known in the field of pharmacology. It is thus well established that a therapeutically useful additive combination is one in which the effect of the combination is greater than the larger ofthe effects produced by each ofthe components at the same concentrations as in the mixture. Thus, in the present case, a given formulation containing x wt% of component (a) and y wt% of component (b) has an activity which is at least as great as the activity of a formulation containing, as sole active ingredient, either x wt% component (a) or y wt% component (b). In such additive combinations, the active ingredients are typically operating via different physiological pathways. In the present case, for example, component (a) and component (b) are believed to be inhibiting separate RSV proteins. An additive combination is therapeutically useful because it can achieve a therapeutically useful effect using lower concentrations of each active component. This enables the side-effects of the medication to be minimised. Thus, the additive combination can be formulated so that each active ingredient is present at a concentration which is subclinical in cells other than the target disease cells. The additive combination is nevertheless therapeutically effective in target cells which respond to both ingredients. As regards component (a), an inhibitor ofthe RSV fusion protein can be identified by an assay comprising: (a) labelling RSV with octadecyl rhodamine dye (Rl 8); (b) pre-incubating the labelled virus with Hep-2 cells seeded in a 6-well plate at 1 hour for 4°C; (c) removing unattached virus; (d) adding the candidate fusion protein inhibitor; (e) incubating the 6-well plates at 37°C for 1 hour; and (f) determining any increase in fluorescence, typically using a fluorescence microscope. In the above assay, any increase in fluorescence signifies a fusion event. Thus, if no increase in fluorescence is detected, 100% inhibition is achieved. If the increase in fluorescence is equal to that observed with a corresponding assay in which a control of growth medium and solvent (e.g., growth medium with 10% fetal bovine serum and DMSO) is used in step (d) in place ofthe candidate fusion protein inhibitor, 0% inhibition is achieved. Accordingly the % inhibition achieved with the candidate fusion protein inhibitor can be determined by quantitative assessment ofthe fluorescence in step (f). As used herein, component (a) is typically a compound which achieves at least 10%, more typically at least 30%, preferably at least 50% and most preferably at least 75%, inhibition ofthe RSV fusion protein as determined by the above assay. Typically, component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof,
wherein: X is a direct link or Cι-6 alkyl; said Cι.6 alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCORi or S(O)n-Cι.6 alkyl; Y is R4, NR^, NCOI ,, =N-OR4, -CONHR4, COOR4, -OR , aryl, heteroaryl, cyclyl or heterocyclyl, where » and R5 are H or Cι-6 alkyl; Z is CRδR7, where R^ and R7 are independently H, or straight, branched or cyclic Cι-6 alkyl; n is 1-2; Ri is CONl^Rs, CC^ , or Ci-6 alkyl, said Cι.6 alkyl can be optionally substituted with OI^ or NRsRg; Rg. and R are each independently H, Cι-6 alkyl, SO2R5, CO2 1 or COR4; R2 is selected from the group consisting of NH2, CONRόR7, heteroaryl, C2.6 alkenyl, CO2R4, N=CPh2, C(=NH)NH2 and Cι-6 alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NRioRπ. OSO2R4 and
Rio and Rn are each independently selected from the group consisting of H, Cι-6 alkyl, C3-6 cycloalkyl, CO2R4, COR, and SO2R4; - R3 is selected from the group consisting of (1) CO2R9; (2) Cι.6 alkyl optionally substituted with CN, OR» or NR^R7; and (3) C2.6 alkenyl substituted with CN; Q is a member selected from the group consisting of
A is C or N, optionally substituted with H, halogen, -6 alkyl, C2-6 alkenyl, cyano-Ci- 6 alkyl, aryl, benzoaminocarbonyl, hydroxybenzyl, SO2NR4R5 or C3-6 cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond; B is C or N; where B is C it may be optionally substituted by H, .6 alkyl, NO2, CN, halogen, COR4, COOR4, CONHR4C(=NH)NH2 or C(=NOH)NH2. Typically, at least two of Ri, R2 and R are hydrogen, and the other is hydrogen or -C(NH)-NH2. Preferably, all of Rh R2 and R3 are hydrogen. Typically, either -X-Y is H, or X is a Cι-C6 alkyl ene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR'R". -COR, -SO2R or phenyl, wherein Ry and R7 are the same or different and represent a Cι-C4 alkyl group. Typically, Z is -CH2-. Typically, Q is a moiety
wherein B is -CH- or -N-, A. is -C(O)- or -NH- and A2 is -CH2-, -CHR'- or -NR."-, wherein R; is a halogen atom and R7 represents a hydrogen atom or a Cι-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, -SO2-(C,-C6 alkyl), -SO2-N(Cι-C6 alkyl)2 or -(CO-NH)a-(Cι-C4 alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent. Particularly preferred compounds of the invention are compounds of formula (la) and pharmaceutically acceptable salts thereof
wherein - B, X and Y are as described in formula (I) above D is cyclopropyl, ethyl, 4-cyanobutyl, isopropenyl, methylsulfonyl, dimethylsulfamoyl, benzylaminocarbamoyl or para-hydroxybenzyl Component (a) can also be a compound of formula (II), or a pharmaceutically acceptable salt thereof, wherein: each X is the same or different and is CH or N; - each R\ is the same or different and is Cι.6 alkyl, halogen, hydroxy, phenyl or (CH2)m=NH2; n is 1 or 2; R2 is C i -6 alkoxy or C ι .6alkoxy-phenyl ; R3 is Cι-6alkyl; - L2 is -CH2- or -NH-; Y is Cι-6 alkyl or Cι.6 alkenyl; Z is H, N(R4)2-, -C(=O)-R5, -C(=CH2)-R5, -CH(OH)-R5, -CH(CH3)-R5, -CH(OCH3)- R5; each R4 is the same or different and is H, Ci-β alkyl. - R5 is Cι-6 alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and m-1-6 For the avoidance of doubt, when Li is -CHR2-CO-, the carbonyl moiety is attached to the phenyl or pyridine ring. Typically, Li is -CH2-. Typically, L2 is -NH-. Typically, Ri is methyl or hydroxy. Typically, n is 2. Typically, each Ri is different. Typically, Y is Cι-C4 alkyl. Typically, Z is -NH2. Other preferred compounds of formula (II) are compounds of formula
wherein: X is C or N; Ri is Cι-6 alkyl, halogen, phenyl or (CH2)m=NH2; R2 is C i -6 alkoxy or C ι -6alkoxy-phenyl ; R3 is Cι.6alkyl; Y is Cι-6 alkyl or Cι-6 alkenyl; Z is H, NR4, -C(=O)-R5, -C(=CH2)-R5, -CH(OH)-R5, -CH(CH3)-R5, -CH(OCH3)-R5; R4 is H, Cι-6 alkyl. R5 is Cι-6 alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl m=l-6 Component (a) can also be a compound of formula (III), or a pharmaceutically acceptable salt thereof,
wherein X is -N=C- or -CH=CH-; Ri is H, hydroxyl, alkyl, halogen, nitro or alkoxy; said alkoxy being optionally monosubstituted with carboxy, amino, monoalkylamino, dialkylamino or acetoamino; R2 is pyrazolyl, triazolyl or tetrazolyl and optionally substituted by amino or alkyl. Component (a) can also be a compound of formula (IV), or a pharmaceutically acceptable salt thereof.
The compound of formula (IV) is 4,4'-Bis-(4,6-bis-{3-[bis-(2-carbamoyl-ethyl)- sulfamoyl]-phenylamino}-[l,3,5]triazin-2-ylamino)-biphenyl-2,2'-disulfonic acid. Preferably, component (a) is: l-Cyclopropyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- imidazo[4,5-c]pyridin-2-one {2-[2-(l,2-Dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l-yl]]ethyl}-diethyl- amine {2-[2-(3-Iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]-ethyl}-dimethyl- amine l-Isopropenyl-3-[l-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- benzoimidazol-2-one 1 -(4-Hydroxy-benzyl)-3-[ 1 -(3-methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1,3- dihydro-benzoimidazol-2-one 1 -Isopropenyl-3 -[ 1 -(3 -oxo-butyl)- 1 H-benzoimidazol-2-ylmethyl] -1,3 -dihydro- benzoimidazol-2-one 1 -Ethyl-3-[ 1 -(2-hydroxy-2-phenyl-ethyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3- dihydro-benzoimidazol-2-one 1 -Ethyl-3 -[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl] - 1 ,3-dihydro- benzoimidazol-2-one 7- [2-(3 -Isopropenyl-2-oxo-2 , 3 -dihydrobenzoimidazol- 1 -ylmethyl)-benzoimidazol- 1 - yl]-heptanenitril 5-{3-[l-(3-Methanesulfonyl-propyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3- dihydro-benzoimidazol- 1 -yl} -pentanenitrile 3-[l-(3-Methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro- benzoimidazol- 1 -carboxylic acid benzylamide l-Methanesulfonyl-3-[l-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3- dihydro-benzoimidazol-2-one 3-[l-(3-Methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro- benzoimidazol-1-sulfonic acid dimethylamide l-Isopropenyl-3-(l-propyl-lH-benzoimidazol-2-ylmethyl)-l,3-dihydro-imidazo[4,5- c]pyridine-2-one Bis(5-amidino-2-benzimidazolyl)-methane 2- {2-[ 1 -[ 1 -(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol- 1 - ylmethyl} -6-methyl-pyridin-3-ol or a pharmaceutically acceptable salt thereof. In a further embodiment, the composition contains an RSV fusion inhibitor, as described above, and a benzodiazepine identifiable as having anti-RSV activity by the method of Example 8. Typically, component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,
wherein: R1 represents Cι.6 alkyl, aryl or heteroaryl; R2 represents hydrogen or Cι-6 alkyl; each R3 is the same or different and represents halogen, hydroxy, Cι-6 alkyl, Cι.6 alkoxy, Cι-6 alkylthio, Ci-e haloalkyl, Cι.6 haloalkoxy, amino, mono(Cι.6 alkyl)amino, di(Cι-6 alkyl)amino, nitro, cyano, -CO2R7, -CONR'R , -NH-CO-R , -S(O)R'- -S(O)2R;, -NH-S(O)2R, -S(O)NR/R or -S(O)2NR/R , wherein each R and R; is the same or different and represents hydrogen or Cι.6 alkyl; n is from 0 to 3; - R4 represents hydrogen or C 1-6 alkyl; R5 represents Cι.6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι-6 alkyl)-, heteroaryl-(C i-6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(Cι.6 alkyl)- aryl-C(O)- C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6; - X represents -CO-, -S(O)- or -S(O)2-; and R6 represents Cι.6 alkyl, hydroxy, Cι-6 alkoxy, Cι.6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl -(Cι.6 alkyl)-, heteroaryl-(Cι.6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(Cι-6 alkyl)-, aryl-(Ci-6hydroxyalkyl)-, heteroaryl-(Cι-6 hydroxyalkyl)-, carbocyclyl-(Cι-6 hydroxyalkyl)-, heterocyclyl-(Cι-6hydroxyalkyl)-, aryl-(Cι-6 alkyl)-O-, heteroaryl-(Cι-6 alkyl)-O-, carbocyclyl-(Cι-6 alkyl)-O-, heterocyclyl-(Cι-6 alkyl)-O- or -NR'R^ wherein each Rf and R; is the same or different and represents hydrogen, Cι-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl- (Ci-6 alkyl)-, heteroaryl-(Ci-6 alkyl)-, carbocyclyl-(Cι-6 alkyl)- or heterocyclyl-(Cι-6 alkyl)-. Typically, R and R are not both hydrogen. As used herein, a Cι-6 alkyl group or moiety is a linear or branched alkyl group or moiety containing from 1 to 6 carbon atoms, such as a Cι.4 alkyl group or moiety. Examples of C alkyl groups and moieties include methyl, ethyl, n-propyl, t-propyl, n-butyl, t-butyl and t-butyl. For the avoidance of doubt, where two alkyl moieties are present in a group, the alkyl moieties may be the same or different. As used herein, a hydroxyalkyl group is typically a said alkyl group that is substituted by one or more hydroxy groups. Typically, it is substituted by one, two or three hydroxy groups. Preferably, it is substituted by a single hydroxy group. Preferred hydroxyalkyl groups are (monohydroxy)ethyl groups. As used herein, an acyl group is a C2. acyl group, for example a group -CO-R, wherein R is a said -6 alkyl group. As used herein, an aryl group is typically a Cό-io aryl group such as phenyl or naphthyl. Phenyl is preferred. An aryl group may be unsubstituted or substituted at any position. Typically, it carries 0, 1, 2 or 3 substituents. Suitable substitutents on an aryl group include halogen, Cι-6 alkyl, C2-7 acyl, hydroxy, Cι-6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι.6 alkyl)carbamoyl, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, -CO2R, -CONR , -S(O)R7, -SCOfcR', -S(O)NRR , -S(O)2NRR -NH-S(O)2R; or -NH-CO-R7, wherein each R' and R is the same or different and represents hydrogen or Cι-6 alkyl. Examples of suitable substituents on an aryl group include halogen, Cι-6 alkyl, C2- η acyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι-6 alkyl)carbamoyl, amino, mono(Cι-6 alkyl)amino, di(d.6 alkyl)amino, -CO2R/, -CONR'R", -S(0)R', -S(O)2R, -S(O)NRR/, -NH- S(O)2R; or -NH-CO-R7, wherein each R' and R1' is the same or different and represents hydrogen or Cι-6 alkyl. Preferred substituents on an aryl group include halogen, Cι.6 alkyl, C2.7 acyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, Cι.6 haloalkyl, Cι-6 haloalkoxy, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro, cyano, -CO-fil, -S^R', -S^R' and -S(O)2NR/R/, wherein each R1 and R11 is the same or different and represents hydrogen or C alkyl. Examples of preferred substituents on an aryl group include halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, mono(Cι-6alkyl)amino, di(Cι.6 alkyl)amino, nitro and cyano. Particularly preferred substituents include fluorine, chlorine, bromine, iodine, Cι-4 alkyl, C2^ acyl, hydroxy, C alkoxy, CM alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(CM alkyl)amino, di(CM alkyl)amino, nitro, -CO2R , -S(O)2R and -S(O)2NH2, wherein R' represents Cι-2 alkyl. Examples of particularly preferred substituents include fluorine, chlorine, bromine, C alkyl, CM alkoxy, CM haloalkyl and nitro. As used herein, references to an aryl group include fused ring systems in which an aryl group is fused to a monocyclic carbocyclyl, heterocyclyl or heteroaryl group or to a fused group which is a monocyclic carbocyclyl, heterocyclyl or heteroaryl group which is fused to a phenyl ring. Typically, said fused ring systems are systems in which an aryl group is fused to a monocyclic carbocyclyl, heterocyclyl or heteroaryl group. Preferred such ring systems are those wherein an aryl group is fused to a fused group which is a monocyclic heterocyclyl or heteroaryl group or to a monocyclic carbocyclic group fused to a phenyl ring, in particular those wherein an aryl group is fused to a heterocyclyl or heteroaryl group. Examples of such fused ring systems are groups in which a phenyl ring is fused to a thienyl group or to a tetrahydrofuranyl group to form a benzothienyl or dihydrobenzofuranyl group. Further examples of such fused rings are groups in which a phenyl ring is fused to a dioxanyl group, a pyrrolyl group or a 2,3-dihydroinden-l-one group to form a benzodioxinyl, indolyl or a 9H-fluoren-9-one group. As used herein, a carbocyclyl group is a non-aromatic saturated or unsaturated monocyclic hydrocarbon ring, typically having from 3 to 6 carbon atoms. Preferably it is a saturated hydrocarbon ring (i.e. a cycloalkyl group) having from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. It is preferably cyclopentyl or cyclohexyl. A cycloalkyl group may be unsubstituted or substituted at any position. Typically, it carries 0, 1, 2 or 3 substituents. Suitable substitutents on a carbocyclyl group include halogen, Cι.6 alkyl, C2.7 acyl, hydroxy, Cι.6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, nitro, cyano, carbamoyl, mono(C].6 alkyl)carbamoyl, di(Cι.6 alkyl)carbamoyl, amino, mono(Cι.6 alkyl)amino, di(Cι-6 alkyl)amino, oxo, -CO2R, -CONR'R , -S(0)R', -S(O)2R, -S(O)NRR , -S(O)2NRR , -NH- S(O)2R or -NH-CO-R7, wherein each R' and R^ is the same or different and represents hydrogen or Cι-6 alkyl. Examples of suitable substitutents on a carbocyclyl group include halogen, Cι-6 alkyl, C2-7 acyl, hydroxy, Cι-6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι.6 alkyl)carbamoyl, amino, mono(Cι^ alkyl)amino, di(Cι.6 alkyl)amino, -CO2R, -CONR'R", -8(0)^, -S(O)2R/, -S^NR'R", -NH-S(O)2R or -NH-CO-R', wherein each R; and R/; is the same or different and represents hydrogen or Cι-6 alkyl. Preferred substituents on an carbocyclyl group include halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro, cyano and oxo. Examples of preferred substituents on an carbocyclyl group include halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro and cyano. Particularly preferred substituents include fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl, nitro and oxo. Examples of particularly preferred substituents include fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. Further examples of particularly preferred substituents include fluorine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. As used herein, a heterocyclyl group is a non-aromatic saturated or unsaturated carbocyclic ring typically having from 5 to 10 carbon atoms, in which one or more, for example 1, 2 or 3, ofthe carbon atoms is replaced by a heteroatom selected from N, O and S. Saturated heterocyclyl groups are preferred. Examples include tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, dioxolanyl, thiazolidinyl, tetrahydropyranyl, piperidinyl, dioxanyl, piperazinyl, morpholinyl, thiomorpholinyl and thioxanyl. Further examples include dithiolanyl, oxazolidinyl, tetrahydrothiopyranyl and dithianyl. Piperazinyl, piperidinyl and morpholinyl are preferred. As used herein, references to a heterocyclyl group include fused ring systems in which a heterocyclyl group is fused to a phenyl group. Preferred such fused ring systems are those wherein a 5- to 6-membered heterocyclyl group is fused to a phenyl group. An example of such a fused ring system is a group wherein a lH-imidazol-2(3H)-onyl group or a imidazolidin-2-onyl group is fused to a phenyl ring to form a lH-benzo[c/]imidazol-2(3H)- onyl group. Most preferably, however, a heterocyclyl group is monocyclic. A heterocyclic group may be unsubstituted or substituted at any position. Typically, it carries 0, 1 or 2 substituents. Suitable substitutents on a heterocyclyl group include halogen, Cι-6 alkyl, C2.7 acyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, Cι.6 haloalkyl, Cι-6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι-6 alkyl)carbomyl, amino, mono(Cι-6 alkyl)amino, di(Cι.6 alkyl)amino, oxo, -CO.R', -CONR'R , -S(0)R', -S(O)2R/, -S^NR'R", -S(O)2NRR//, -NΗ- S(O)2R or -NΗ-CO-R , wherein each Rf and R7 is the same or different and represents hydrogen or Cι-6 alkyl. Examples of suitable substitutents on a heterocyclyl group include halogen, Cι-6 alkyl, C2-7 acyl, hydroxy, Cι-6 alkoxy, Cι.6 alkylthio, Cι.6 haloalkyl, Cι.6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι-6 alkyl)carbomyl, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, -COiR1, -CONR , -S(O)R , -S(O)2R/, -S(O)NRR/, -NH-S(O)2R or -NH-CO-R', wherein each R1 and R; is the same or different and represents hydrogen or Cι-6 alkyl. Preferred substituents on a heterocyclyl group include halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, mono(Cι.6 alkyl)amino, di(Cι.6 alkyl)amino, nitro, cyano and oxo. Examples of preferred substituents on a heterocyclyl group include halogen, Cι.6 alkyl, Cι-6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, mono(Ci.6 alkyl)amino, di(Cι.6 alkyl)amino, nitro and cyano. Particularly preferred substituents include fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl, nitro and oxo. Examples of particularly preferred substituents include fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. Further examples of particularly preferred substituents include fluorine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. Most preferably, a heterocyclyl group is unsubstituted or substituted by one or two Cι-2 alkyl groups. As used herein, a halogen is typically chlorine, fluorine, bromine or iodine. It is preferably chlorine, fluorine or bromine. It is more preferably chlorine or fluorine. As used herein, an alkoxy group is typically a said alkyl group attached to an oxygen atom. An alkylthio group is typically a said alkyl group attached to a thio group. A haloalkyl or haloalkoxy group is typically a said alkyl or alkoxy group substituted by one or more said halogen atoms. Typically, it is substituted by 1, 2 or 3 said halogen atoms. Preferred haloalkyl and haloalkoxy groups include perhaloalkyl and perhaloalkoxy groups such as -CX3 and -OCX3 wherein X is a said halogen atom, for example chlorine or fluorine. Particularly preferred haloalkyl groups are -CF3 and -CC13. Particularly preferred haloalkoxy groups are -OCF3 and -OCCl3. As used herein, a heteroaryl group is typically a 5- to 10 membered aromatic ring, such as a 5- or 6-membered ring, containing at least one heteroatom, for example 1, 2 or 3 heteroatoms, selected from O, S and N. Examples include pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, furanyl, thienyl, pyrazolidinyl, pyrrolyl, oxadiazolyl, isoxazolyl, thiadiazolyl, thiazolyl, imidazolyl and pyrazolyl groups. Further examples include oxazolyl and isothiazolyl. Preferred heteroaryl groups are pyridyl, thienyl, oxazolyl, isoxazolyl, furanyl and pyrazolyl. Examples of preferred heteroaryl groups are pyridyl, thienyl, isoxazolyl and furanyl. As used herein, references to a heteroaryl groups include fused ring systems in which a heteroaryl group is fused to a phenyl group. Preferred such fused ring systems are those wherein a 5- to 6-membered heteroaryl group is fused to a phenyl group. Examples of such fused ring systems are benzofuranyl, benzothiophenyl, indolyl, benzimidazolyl, benzoxazolyl, quinolinyl, quinazolinyl and isoquinolinyl moieties. Most preferably, however, a heterocyclyl group is monocyclic. A heteroaryl group may be unsubstituted or substituted at any position. Typically, it carries 0, 1, 2 or 3 substituents. Suitable substitutents on a heteroaryl group include halogen, Cι-6 alkyl, C2-7 acyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι-6 alkyl)carbamoyl, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, -CO2R/, -CONRV, -S(O)R.', -S(O)2R;, -S(O)NR/R/ , -SCOfcNR'R", -NH- S(O)2R or -NH-CO-R7, wherein each R' and R^ is the same or different and represents hydrogen or Cι.6 alkyl. Examples of suitable substitutents on a heteroaryl group include halogen, Cι-6 alkyl, C2.7 acyl, hydroxy, Cι-6 alkoxy, Cι.6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι.6 alkyl)carbamoyl, amino, mono(Cι.6 alkyl)amino, di(Cι-6 alkyl)amino, -røR', -CONR , -8(0)^, -S(O)2R, -S(O)NRR , -NH-S(O)2R or -NH-CO-R, wherein each R and R is the same or different and represents hydrogen or Cι-6 alkyl. Preferred substituents on a heteroaryl group include halogen, Cι-6 alkyl, Cι.6 alkoxy, Cι-6 alkylthio, Cι.6 haloalkyl, Cι-6 haloalkoxy, mono(Cι-6 alkyl)amino, di(Cι.6 alkyl)amino, nitro and cyano. Particularly preferred substituents include fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. Further preferred substituents include fluorine, chlorine, bromine, Cι.2 alkyl, Cι.2 haloalkyl and di(Cι.2 alkyl)amino. As used herein, references to a heteroaryl group include fused ring systems in which a heteroaryl group is fused to a monocyclic said aryl, carbocyclyl or heterocyclyl group, or to a further heteroaryl group. Preferred such ring systems are those wherein a heteroaryl group is fused to an aryl group, for example a phenyl group. An example of such a fused ring system is a group wherein a thienyl group is fused to a phenyl ring to form a benzothienyl group. A further example of such a fused ring system is a group wherein a furanyl group is fused to a phenyl ring to form a benzofuranyl group. When R1 in the formula (V) is an aryl or heteroaryl group it is typically unsubstituted or substituted by one, two or three substituents selected from halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl or Cι-6 haloalkoxy. Preferably, it is unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl or CM haloalkoxy. More preferably, it is unsubstituted or substituted by a single fluorine, chlorine, Cι-2 alkyl, Cι-2 alkoxy, Cι-2 alkylthio, Cι-2 haloalkyl or Cι-2 haloalkoxy substituent. Typically, R1 in the formula (V) is Cι-6 alkyl or aryl. Preferably, R1 is Cι.2 alkyl or aryl. More preferably, R1 is Cι-2 alkyl or phenyl. More preferably, R1 is phenyl. Typically, R2 in the formula (V) is hydrogen or C alkyl. Preferably, R2 is hydrogen. Typically, R3 in the formula (V) is halogen, hydroxy, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(CM alkyl)amino or di(C alkyl)amino. Preferably, R is fluorine, chlorine, bromine, Cι.2 alkyl, Cι.2 alkoxy, Cι-2 alkylthio, Cι-2 haloalkyl, Cι.2 haloalkoxy, amino, mono(Cι.2 alkyl)amino or di(Cι-2 alkyl)amino. More preferably, R3 is methyl, trifluoromethyl, fluorine, chlorine or bromine. Most preferably, R3 is methyl or chlorine. An example of a most preferred group is when R3 is chlorine. Typically, n in the formula (V) is 0, 1 or 2. Preferably, n is 0 or 1. Typically, R4 in the formula (V) is hydrogen or Cι-4 alkyl. Preferably, R4 is hydrogen or Ci-2 alkyl. More preferably, R4 is hydrogen or methyl. Most preferably, R4 is hydrogen. When R5 in the formula (V) is a heterocyclyl group, it is typically attached via a carbon atom. Typically, R5 is Cι-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)-, aryl- C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6. Examples of typical R5 groups are those wherein R5 is Cue alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι-4 alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)- or -XR6. Preferably, R5 in the formula (V) is CM alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(Cι-2 alkyl)-, for example benzyl, heteroaryl-(Cι-2 alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6. Examples of preferred R5 groups are those wherein R5 is CM alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(Cι.2 alkyl)-, for example benzyl, heteroaryl-(Cι-2 alkyl)- or -XR6. More preferably, R5 in the formula (V) is CM alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl- CH2-, furanyl-CH2-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR6. Examples of more preferred R5 groups are those wherein R5 is CM alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH2-, furanyl- CH2- or -XR6. Most preferably, R5 in the formula (V) is phenyl-CH2-, furanyl-CH2-, -C(O)-C(O)- thienyl or -XR6. Examples of most preferred R5 groups are those wherein R5 is phenyl-CH2-, furanyl-CH2- or -XR6. Typically, X in the formula (V) is -CO-, -S(O)- or -S(O)2-. Preferably, X is -CO- or
-S(O)2-. When R6 in the formula (V) is a group -NR'R^ and either R or R includes an aryl, heteroaryl, carbocyclyl or heterocyclyl moiety it is typically unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι.6 haloalkyl, Cι.6 haloalkoxy, nitro and cyano. Preferably, the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl, CM haloalkoxy and nitro. An example of preferred substitution is when the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM haloalkyl and nitro. More preferably, the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, Cι.2 alkyl, Ci.2 alkoxy, Cι-2 alkylthio, Cι.2 haloalkyl and nitro. An example of more preferred substitution is when the aryl, heteroaryl, carbocyclyl or heterocyclyl moiety is unsubstituted or substituted by a single fluoro, chloro, methyl, methoxy or nitro substituent. When R or R" is a heteroaryl or heterocyclyl group, it is attached via a carbon atom. Typically, R' and R" in the group in the formula (V) are not both hydrogen. Typically, each R' and R^is the same or different and represents hydrogen, CM alkyl, aryl, heteroaryl, carbocyclyl, aryl-(CM alkyl)- or heteroaryl-(CM alkyl)-. Examples of typical Rf and R" groups are those wherein each R' and R is the same or different and represents hydrogen, CM alkyl, phenyl, heteroaryl, for example thienyl, carbocyclyl, for example cyclohexyl or cyclopentyl, or phenyl-(CM alkyl)-. Further examples of typical R' and R7/ groups are those wherein each R and R is the same or different and represents hydrogen, Ci. 4 alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH2)-. Preferably, each R' and R!/ is the same or different and represents hydrogen, CM alkyl, phenyl, phenyl-CH2-, cyclohexyl or cyclopentyl. More preferably, one of Rf and R represents hydrogen. Most preferably, one of R and R is hydrogen and the other is CM alkyl, phenyl, phenyl-CH2-, cyclohexyl or cyclopentyl. As an additional preference, one of R and R/f is hydrogen and the other is CM alkyl, phenyl, thienyl or phenyl-CH2-. Typically, R6 in the formula (V) is Cι-6 alkyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocycl yl-(CM alkyl)-, aryl -(CM hydroxyalkyl)-, heteroaryl-(Cι. 4 hydroxyalkyl)-, carbocyclyl-(CM hydroxyalkyl)-, heterocyclyl-(CM hydroxyalkyl)-, aryl- (CM alkyl)-O-, heteroaryl-(CMalkyl)-O-, carbocyclyl-(CM alkyl)-O-, heterocyclyl-(CM alkyl)-O- or -NR'R' wherein R' and R" are as defined above. Examples of typical R6 groups are those wherein R6 is Cι.6 alkyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)- or -NR'R'7 wherein R' and R" are as defined above. Preferably, R6 in the formula (V) is Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, aryl, for example phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl and indolyl, heteroaryl, for example thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl and benzofuranyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperazinyl, piperidinyl, morpholinyl and lH-benzo[c ]imidazol- 2(3H)-onyl, phenyl-(Cι-2 alkyl)-, phenyl-(Cι-2 alkyl)-O-, phenyl-(Cι-2 hydroxyalkyl)-, heteroaryl-(Cι-2 hydroxyalkyl)-, heteroaryl-(Cι-2 alkyl)- or -NR'R'7 wherein R! and R are as defined above. Examples of preferred R6 groups are those wherein R is CM alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example N-heterocyclyl, phenyl-(Cι-2 alkyl)-, for example benzyl, heteroaryl-(Cι-2 alkyl)- or -NR'R' wherein R and R are as defined above. More preferably, R6 in the formula (V) is CM alkyl, CM alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9Η-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(Cι-2 alkyl)-, phenyl-CH2-CH(OH)-, phenyl- CH(OH)-CH2-, phenyl-(Cι-2 alkyl)-O-, lH-benzo[^imidazol-2(3H)-onyl or -NR'R" wherein Rf and R/; are as defined above. Example of most preferred R6 groups are those wherein R6 is CM alkyl, phenyl, thienyl, furanyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, isoxazolyl, piperidinyl, for example N-piperidinyl, morpholinyl, for example N-morpholinyl, piperazinyl, for example N-piperazinyl, or -NR'R wherein R and R" are as defined above. Preferred compounds ofthe formula (V) are those in which: - R1 is Cι-6 alkyl or aryl; R2 is hydrogen or C alkyl; R3 is halogen, hydroxy, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(Cι-4 alkyl)amino or di(C alkyl)amino or, preferably, R is fluorine, chlorine, bromine, Cι.2 alkyl, C1-2 alkoxy, C1-2 alkylthio, C1.2 haloalkyl, Cι-2 haloalkoxy, amino, mono(Cι-2 alkyl)amino or di (Cι-2 alkyl)amino; n is 0, 1 or 2; R4 is hydrogen or CM alkyl; R5 is C ι-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)-, aryl- C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6; X is -CO-, -S(O)- or -S(O)2-; and R6 is C 1-6 alkyl, hydroxy, Cι.6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl -(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)-, aryl-(CM hydroxyalkyl)-, heteroaryl-(CM hydroxyalkyl)-, carbocyclyl-(CM hydroxyalkyl)-, heterocyclyl-(CM hydroxyalkyl)-, aryl-(Cι-4 alkyl)- O-, heteroaryl-(CM alkyl)-O-, carbocyclyl-(CM alkyl)-O-, heterocyclyl-(CM alkyl)- O- or -N 'R'', wherein each R' and R is the same or different and represents hydrogen, CM alkyl, aryl, heteroaryl, carbocyclyl, aryl-(CM alkyl)- or heteroaryl-(Cι- alkyl)-, the aryl moiety in the R1 group being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι.6 alkyl, Cι.6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl or
Ci-6 haloalkoxy; the aryl and heteroaryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι.6 alkyl, C2.7 acyl, hydroxy, Cι.6 alkoxy, Cι-6 alkylthio, Ci-6 haloalkyl, Cι-6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι.6 alkyl)carbamoyl, di(Cι-6 alkyl)carbomyl, amino, mono(Cι-6 alkyl)amino, di(Cι.6 alkyl)amino,
-CO^, -CONR'R", -S(O)R', -8(0)2^, -S(O)NRR/, -S(O)2NR/R , -NH-S(O)2R/ or -NH-CO-
R, wherein each R' and R is the same or different and represents hydrogen or Cι.6 alkyl; the carbocyclyl and heterocyclyl moieties in the groups R5 and R6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι-6 alkyl, C2- acyl, hydroxy, Ci-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι.6 haloalkoxy, nitro, cyano, carbamoyl, mono(Cι-6 alkyl)carbamoyl, di(Cι-6 alkyl)carbomyl, amino, mono(Cι-6 alkyl)amino, di(Cι.6 alkyl)amino, oxo, -CU2R7, -CONR'R", -S(0)R', -SCOfcR', -S(O)NRR/, -S(O)2NR/R/, -NH-
S(0)2R' or -NH-CO-R , wherein each R1 and R/ is the same or different and represents hydrogen or Cι-6 alkyl; and the alkyl moieties in the aryl-(Cι-4 alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(Cι-4 alkyl)- groups of R6 being unsubstituted or substituted by one or two hydroxy substituents. Preferably, in these preferred compounds of formula (V), the aryl, heteroaryl and carbocyclyl moieties in the groups R' and R" are unsubstituted or substituted by 1 , 2 or 3 substituents selected from halogen, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Ci-6 haloalkoxy, nitro and cyano. Further preferred compounds of formula (V) are those wherein: R1 is Ci-2 alkyl or phenyl; R2 is hydrogen or Cι-4 alkyl; R3 is methyl, trifluoromethyl, fluorine, chlorine or bromine; - n is 0 or 1 ; R4 is hydrogen or Cι-2 alkyl; R5 is CM alkyl, aryl, for example phenyl and dihydrobenzofuranyl, heteroaryl, for example thienyl, furanyl, isoxazolyl, pyridyl and benzothienyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperidinyl, morpholinyl and piperazinyl, phenyl-(Cι. alkyl)-, for example benzyl, heteroaryl-(Cι- 2 alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6, provided that when R5 is heterocyclyl it is attached via a carbon atom; X is -CO-, -S(O)- or -S(O)2-; and R6 is Ci-6 alkyl, Cι-6 alkoxy, Cι.6 alkylthio, aryl, for example phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl and indolyl, heteroaryl, for example thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl and benzofuranyl, carbocyclyl, for example cyclopentyl and cyclohexyl, heterocyclyl, for example piperazinyl, piperidinyl, morpholinyl and lH-benzo[d]imidazol-2(3H)-onyl, phenyl-(C 1-2 alkyl)-, phenyl-(Cι.2 alkyl)-O-, phenyl-(C 1-2 hydroxyalkyl)-, heteroaryl- (C 1.2 hydroxyalkyl)-, heteroaryl-(C 1 -2 alkyl)- or -NR'R" wherein each R' and R" is the same or different and represents hydrogen, CM alkyl, phenyl, heteroaryl, for example thienyl, carbocyclyl, for example cyclohexyl or cyclopentyl, or phenyl-(Cι--ι alkyl)-, the phenyl moiety in the R1 group being unsubstituted or substituted by one or two substituents selected from fluorine, chlorine, bromine, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl or CM haloalkoxy; the aryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1 , 2 or 3 substituents selected from halogen, Cι-6 alkyl, C2.7 acyl, hydroxy, Cι-6 alkoxy, Ci-6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro, cyano, -CO2R', -S(O)R ,-S(O)2R/ and -S(O)2NR/R/ , wherein each R and R is the same or different and represents hydrogen or CM alkyl; the heteroaryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι.6 alkyl, Cι-6 alkoxy, Ci-6 alkylthio, Ci-6 haloalkyl, Cι.6 haloalkoxy, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro and cyano; and the carbocyclyl and heterocyclyl moieties in the groups R and R being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, Cι-6 alkyl, Cι.6 alkoxy, Cι-6 alkylthio, Cι-6 haloalkyl, Cι-6 haloalkoxy, mono(Cι-6 alkyl)amino, di(Cι.6 alkyl)amino, nitro, cyano and oxo; and the alkyl moiety in the phenyl-(Cι-2 alkyl)- and heteroaryl-(Cι-2 alkyl)- groups of R6 being unsubstituted or substituted by a single hydroxy substituent. Preferably, in these further preferred compounds of formula (V), the phenyl, heteroaryl and carbocyclyl moieties in the groups R and R are unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, CM alkyl, Cι-4 alkoxy, Cι-4 alkylthio, CM haloalkyl, CM haloalkoxy and nitro. Particularly preferred compounds of formula (V) are compounds of formula (Va) are pharmaceutically acceptable salts thereof
wherein: R is phenyl or methyl; R3 is methyl or chlorine; n is 0 or 1 ; R4 is hydrogen or methyl; R5 is phenyl-CH2-, furanyl-CH2-, thienyl-C(O)-C(O)- or -XR6; X is -CO- or -S(O)2-; and R6 is C alkyl, CM alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(Cι.2 alkyl)-, phenyl-CH2-CH(OH)-, phenyl-CH(OH)-CH2-, phenyl-(Cι-2 alkyl)-O-, lH-benzo[cfJimidazol-2(3H)-onyl or -NR'R" wherein each R and R is the same or different and represents hydrogen, CM alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CΗ2)-, the phenyl moiety in the group R1 being unsubstituted or substituted by a single fluorine, chlorine, Cι-2 alkyl, Cι-2 alkoxy, Cι-2 alkylthio, C1-2 haloalkyl or C 1.2 haloalkoxy substituent; the aryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1 ,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, CM alkyl, C2-4 acyl, hydroxy, CM alkoxy, Cι-4 alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(CM alkyl)amino, di(C alkyl)amino, nitro, -CO.R, -S(O)2R and -S(O)2NH2, wherein R' represents Cι-2 alkyl; the heteroaryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, Cι-2 alkyl, C1.2 haloalkyl and di(Cι-2 alkyl)amino; and the heterocyclyl and carbocyclyl moieties in the R6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,Cι-4 alkyl, CM alkoxy, CM haloalkyl and nitro. Preferably, R1 in the formula (Va) is phenyl, n is 0, R4 is hydrogen and R5 is -CO- phenyl or -CO-NH-phenyl, wherein the phenyl group in R5 is unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, C1-C2 alkyl, C1-C2 alkoxy, C1-C2 haloalkyl, -CO∑R7 or -S(O)2R/, wherein each R is the same or different and represents Cι-C2 alkyl. Compounds of the formulae (I), (II), (III) or (V) containing one or more chiral centre may be used in enantiomerically or diasteroisomerically pure form, or in the form of a mixture of isomers. For the avoidance of doubt, the chemical structures depicted herein are intended to embrace all stereoisomers ofthe compounds shown, including racemic and non- racemic mixtures and pure enantiomers and/or diastereoisomers. Preferred compounds of the formula (V) are optically active isomers. Thus, for example, preferred compounds of formula (V) containing only one chiral centre include an R enantiomer in substantially pure form, an S enantiomer in substantially pure form and enantiomeric mixtures which contain an excess of the R enantiomer or an excess ofthe S enantiomer. For the avoidance of doubt, the compounds ofthe formula (V) can, if desired, be used in the form of solvates. As used herein, a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base. Pharmaceutically acceptable acids include both inorganic acids such as hydrochloric, sulphuric, phosphoric, diphosphoric, hydrobromic or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulphonic, benzenesulphonic or p-toluenesulphonic acid. Pharmaceutical acceptable bases include alkali metal (e.g. sodium or potassium) and alkaline earth metal (e.g. calcium or magnesium) hydroxides and organic bases such as alkyl amines, aralkyl amines or heterocyclic amines. Most preferably, component (b) is: N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-acetamide; 1 , 1 -Diethyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-propionamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-butyramide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-isobutyramide; 2,2-Dimethyl-N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- propionamide; Cyclopentanecarboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l Hbenzo[e] [1 ,4]diazepin-3-yl)-amide; Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; 3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; 2-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-trifluoromethyl- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)-3 -amide; Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-amide; Piperidine- 1 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yι)-amide; Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4] diazepin-3-yl)-amide; 4-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide; 3-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 4-Methyl-piperazine-l -carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-trifluoromethyl- benzamide; 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide; 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-benzamide Benzo[b]thiophene-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e] [ 1 ,4]diazepin-3 -yl)-amide; 2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l ,4]diazepin-3-yl)-amide; Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-amide; Benzo[b]thiophene-2 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-isonicotinamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-nicotinamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- methanesulfonamide; Propane- 1-sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-amide; Butane- 1-sulfonic acid— (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-amide; 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzenesulfonamide; 3-(2-Nitro-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 3-(3-Nitro-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 3-(4-Nitro-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 3-(2-Methoxy-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 3-(3-Methoxy-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 5-Phenyl-3-(2-trifluoromethyl-benzylamino)- 1 ,3-dihydro-benzo[e] [ 1 ,4]diazepin-2- one; 5-Phenyl-3-(3-trifluoromethyl-berιzylamino)-l,3-dihydro-benzo[e][l,4]diazepin-2- one; 5-Phenyl-3-(4-trifluoromethyl-benzylamino)-l,3-dihydro-benzo[e][l,4]diazepin-2- one; 3-[(Furan-2-ylmethyl)-amino]-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-acetamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazeρin-3-yl)- isobutyr amide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- methanesulfonamide; Furan-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2- methoxy-benzamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-4- methoxy-benzamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-2-nitro- benzamide; 2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(4-Methoxy-phenyl)N-(2-oxo-5-ρhenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(4-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- acetamide; 2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(2- trifluoromethyl-phenyl)-acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-2-(3- trifluoromethyl-phenyl)-acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(4- trifluoromethyl-phenyl)-acetamide; l-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 1 -(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; l-(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; 1 -(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3-p-tolyl-urea; 1 -(2-Fluoro-ρhenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; l-(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; (S)-l-(2-Fluoro-phenyl)-3-(2-oxo-5-ρhenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo [e] [ 1 ,4] diazepin-3-yl)-benzamide; (S)- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-benzamide; 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (S)- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-benzamide ; 6-Fluoro-4H-benzo[l,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; (S)- 6-Fluoro-4H-benzo[l,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-
1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-amide; (S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-4- trifluoromethyl-benzamide; 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazeρin-3-yl)- benzamide; 2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; (S)-2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; lH-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-amide; (S)-lH-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4] diazepin-3 -yl)-amide; 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e] [ 1 ,4]diazepin-3 -yl)-amide; (S)-3-Methoxy-naphthalene-2 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e] [ 1 ,4]diazepin-3 -yl)-amide; N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4]diazepine-3- yl] -4-methoxoy-benzamide; l-(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; l-(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 1 -(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3-(4-trifluoromethyl- phenyl)-urea; 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 - yl)-benzamide; 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)benzamide; 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)benzamide; 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4]diazepin-3-yl)- benzamide; 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)propionamide; 3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-propionamide; 3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-propionamide; N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]-2- methoxy-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- 4-methoxy-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- 2-nitro-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- 4-nitro-benzamide; 4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-l H- benzo [e] [ 1 ,4] diazepin-3 -yl] -benzamide; 2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro- 1 H- benzo [e] [ 1 ,4]diazepin-3 -yl] -benzamide; 4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-lH- benzo[e] [ 1 ,4]diazepin-3-yl]-benzamide; 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-benzamide; 2-Methoxy-N-[5-(3-mehtoxy-phenyl)-2-oxo-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl] -benzamide N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl]-4-nitro-benzamide; 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-benzamide; 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-benzamide; 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid benzyl ester; l-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazeρin-3-yl)-3-(4- trifluoromethoxy-phenyl)-urea; l-(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo [e] [ 1 ,4] diazepin-3 -yl)-urea; l-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; l-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-urea; 1 -(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; 1 -(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [1 ,4] diazepin-3-yl)-urea; 1 -(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydrό- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(2-Methylsulfanyl-phenyl)-3-(2-oxo-5-ρhenyl-2,3-dihydro- lH-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; l-(2,6-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-benzamide; 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; l-(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-urea; l-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; l-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(3-trifluoromethyl- phenyl)-urea; 1 -(3 -Chloro-phenyl)-3 -(2-oxo-5 -phenyl-2 , 3 -dihydro- 1 H-benzo [e] [ 1 ,4] diazepin-3 -yl)- urea; 2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-benzamide; 4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)terephthalamic acid methyl ester; 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-2-propoxy- benzamide; 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide; 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- terephthalamic acid methyl ester; 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-benzamide; 1 -(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3-m-tolyl-urea; 2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-5- sulfamoyl-benzamide; 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3- phenyl-propionamide 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3- phenyl-propionamide ; 3-(2-Fluoro-phenyl)- 1 -methyl- 1 -(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; l-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; l-Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; l-Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; 1 -Butyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; 4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l ,4]diazepin-3-yl)amide; Piperidine- 1 -carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo [e] [ 1 ,4]diazepin-3 -yl)-amide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)acetamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- isobutyramide; Furan-2 -carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; Cyclohexanecarboxylic acid [5-(3chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e] [ 1 ,4]diazepin-3 -yl] -amide; Piperidine-1 -carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l ,4]diazepin-3-yl]-amide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3- yl]isonicotinamide; 5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl]-isobutyr amide; Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- lH-benzo[e][l ,4]diazepin-3-yl]-amide; Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl]-amide; Piperidine- 1 -carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo [e] [ 1 ,4] diazepin-3 -yl] -amide; Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l ,4]diazepin-3-yl)-amide; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-thiophene-2-yl- urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-thiophene-3-yl- urea; Pyridine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; 1 H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3-yl)-amide; 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- nicotinamide; 2-Ethoxy-naphthalene- 1 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo [e] [ 1 ,4]diazepin-3 -yl)-amide; 9-Oxo-9H-fluorene-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; 2-Oxo-2,3-dihydro-benzoimidazole-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- lH-benzo[e][l,4]diazepin-3-yl)-amide; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)carbamic acid tert-butyl ester; (S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l H- benzo[e][l,4]diazepin-3-yl)-amide; (S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid methyl ester; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid ethyl ester; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid isobutyl ester; and 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-thiophene- 2-yl-acetamide, or a pharmaceutically acceptable salt thereof. The compounds of formulae (I), (II), (III) and (IV) are known compounds. They are disclosed, for example, in WO 00/195910, WO 00/004900, WO 03/053344, US-A-4324794 and WO 01/00612, and can be prepared by the processes set out in those documents. WO 00/195910, WO 00/004900, WO 03/053344, US-A-4324794 and WO 01/00612 are incorporated herein by reference. Any ofthe compounds disclosed as fusion protein inhibitors in those documents can be used in the present invention. Compounds of formula (V) may be prepared by reacting glyoxylic acid (HCO- CO2H), benzotriazole and an appropriate benzyl carbamate at reflux in toluene, under Dean- Stark conditions giving the key protected amino acid of formula (II )
The thus obtained amino acid of formula (II7) can then be reacted with a suitable chlorinating agent, such as oxalyl chloride, followed by reaction with a 2- aminobenzophenone of formula (HI7)
to give the intermediate amide of formula (IV7)
which need not be characterized. The compound of formula (IN7) can then be subjected to ammonolysis followed by ring closure in acetic acid containing ammonium acetate to obtain the protected benzodiazepine of formula (V7)
The compound of formula (V7) can then be deprotected using hydrogen bromide in acetic acid to yield the deprotected amine of formula (VI7). Compounds of formula (V), in which R5 is XR6 and X is -CO- can be prepared by reacting a compound of formula (VI7), as defined above, with an acid anhydride in a suitable solvent, preferably pyridine at ambient temperature, or with an acid chloride in a suitable solvent in the presence of a base, preferably in THF at ambient temperature with triethylamine present. Alternatively, the compounds can be produced by reaction of a compound of formula (VI7) with an acid in a suitable solvent in the presence of a base and a coupling agent, preferably in THF at ambient temperature with triethylamine and O- benzotriazol-1-yl-N, N, N', N'-tetramethyluronium hexafluorophosphate (HBTU) present. If the acid chloride used is an amino carbonyl chloride, the compound of formula (V) is a tertiary urea. In the case where R6 is NH-R7, such compounds may be prepared by the reaction of a compound of formula (VI7) with an isocyanate. This reaction is preferably carried out in THF at ambient temperature. Alternatively, the isocyanate may be prepared in situ from the relevant amine and phosgene, in the presence of a base, usually triethylamine, again in THF. Compounds of formula (V), in which R5 is -XR6 and X is -S(O)2- may be prepared by the reaction of a compound of formula (VI7) with a suitable sulfonyl chloride. Similarly, compounds of formula (V), in which R5 is XR6 and X is -S(O)- may be prepared by the reaction of a compound of formula (VI7) with a suitable sulfinyl chloride Compounds of formula (V) in which R5 is not XR6 may be prepared by known methods. For example, a compound of formula (VI7) can be reacted with a compound of formula R5-L, wherein L is a leaving group such as a chlorine atom, a mesylate group or a triflate group. When R5 is aryl or heteroaryl, L can be -B(OH) and the reaction may take place in the presence of copper acetate. Such boronic acid coupling reactions will, of course, be familiar to those of skill in the art. Compounds wherein R5 is aryl or heteroaryl may also be prepared by way of a Buchwald reaction or by reaction of a compound of formula (VI7) with an appropriate fluoroaryl or fluoroheteroaryl compound. Compounds wherein R5 is a heteroaryl group may also be prepared by reaction of a compound of formula (VI7) with a suitable chloroheteroaryl or bromoheteroaryl compound. Compounds wherein R5 is a carbocyclyl group may also be prepared by known methods, for example a compound wherein R5 is cyclohexyl may be prepared by the reaction of a compound of formula (VI7) with cyclohexanone in the presence of a reducing agent. Compounds of formula (V) in which the R5 group is aryl-(Cι-6 alkyl)-, heteroaryl-(G- 6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(G-6 alkyl)- can also be prepared by the reaction of a compound of formula (VI7) with an aldehyde in the presence of a reducing agent. Preferably, such reactions between compounds of formula (VI7) and aldehydes are carried out in a mixture of dichloromethane and acetic acid in the presence of sodium (triacetoxy)borohydride at ambient temperature. In the preparation of the benzodiazepine skeleton, commercially available aminobenzophenone compounds of formula (III7) can be used where possible. Compounds of formula (III7) which are not commercially available can be prepared by known methods, for example by reaction of a Weinreb type amide of formula (VII7)
with a group R'-Li or a Grignard reagent such as R'-MgBr. Preferably this reaction is carried out in THF at -100°C. Compounds of formula (VII7) are known compounds or can be prepared by analogy with known methods. For example, they can be prepared from the reaction of isatoic anhydrides of formula (VIII )
with N,O-dimethyl hydroxylamine under standard reaction conditions. The starting materials of formula (II7), (III7), (VII7), and (VIII7) are known compounds, or may be prepared by analogy with known methods. Further synthetic manipulation ofthe thus obtained compounds of formula (V) may be carried out by conventional methods to achieve further compounds of formula (V). The benzodiazepines of formula (V) can be salified by treatment with an appropriate acid or base. Although the described route to the claimed compounds provides an adequate synthesis for laboratory scale preparations, an alternative route was sought which has potential as a manufacturing route. The same starting material (2-amino-benzophenone) (1) is used in both, however in the alternative route, the benzodiazepine ring system is formed by reaction initially with bromoacetyl bromide (or an equivalent reagent) followed by ring closure with ammonia. These reactions are carried out in a suitable solvent, such as dichloromethane, and at a suitable temperature which may range from -20 to 150°C. In order to protect the NH functionality, at this stage the unsubstituted benzodiazepine is reacted with a base, and an alkylating agent. For instance sodium hydride in DMF followed by addition of 4-methoxy-benzyl chloride gives rise to the intermediate (2) shown below. Further reaction of this material with a base (e.g. potassium tert-butoxide) in a suitable solvent (e.g. THF or DMF) followed by quenching with isoamyl nitrite (or an alternative similar reagent) furnishes the oxime intermediate (3) which may be converted into the racemic primary amine by methods which include the use of hydrogen and a suitable catalyst. This amine then undergoes a Dynamic Kinetic Resolution (DKR) procedure by which the racemic amine in the presence of a suitable optically active acid, and a suitable aldehyde gives rise to precipitation ofthe salt ofthe desired (S)-amine (4) in good yield and exceptionally high enantiomeric excess. A suitable acid for this conversion can be e.g. Camphorsulfonic acid, Boc-phenyl alanine or the like, and a suitable aldehyde may be a benzaldehyde such as 3,5- dichloro salicylaldehyde. The optically amine thus formed may then be transformed into a desired derivative, such as an amide or urea. The amide formations may be carried out using a suitable carboxylic acid and a coupling reagent, or a carbonyl chloride or other suitable reagent, and the ureas prepared using aeither a suitable isocyanate, or alternatively reaction with phosgene followed by a suitable amine. These derivatives thus formed may then have the protecting group removed. This may be carried out in the presence of a Lewis Acid, such as aluminium chloride, boron trifluoride, titanium tetrachloride, or the like. These reactions are carried out in a suitable inert solvent, such as dichloromethane. Reaction temperatures may range from -20 to 150°C, but are typically carried out at room temperature or below.
1. ArNCO
In a particularly preferred embodiment ofthe invention, component (a) is 1- cyclopropyl-3-[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3-dihydro- imidazo[4,5-c]pyridin-2-one, 2-[2-(l,2-dihydro-benzotriazol-l-ylmethyl)-benzoimidazol-l- yl]]ethyl}-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]- ethyl}-dimethyl-amine or a pharmaceutically acceptable salt thereof and component (b) is (S)-l-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea, (S)-2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide, (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl)-benzamide or a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition according to the invention, for use in the treatment ofthe human or animal body. Also provided is the use of (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative, in the manufacture of a medicament for use in treating or preventing an RSV infection. The present invention also provides a method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative. Typically, the amount of component (a) in the composition ofthe invention is from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, based on the total weight ofthe composition. Typically, the amount of component (b) in the composition ofthe invention is from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, based on the total weight ofthe composition. Typically, the total amount of components (a) and (b) in the composition ofthe invention is from 0.05 to 20 wt%, preferably from 0.5 to 10 wt%, more preferably from 2 to 7 wt%, for example about 5 wt%, based on the total weight ofthe composition. RSV is prevalent among children younger than two years of age, adults suffering from asthma, chronic obstructive pulmonary disorder (COPD) or immunodeficiency and the elderly. It is a particularly serious risk amongst children who suffer from chronic lung disease. Accordingly, the said composition or medicament is typically for use in treating a patient who is a child under two years of age, patients with asthma, COPD or immunodeficiency the elderly or persons in long term care facilities. Typically, said child suffers from chronic lung disease. Further, anti-RSV prophylaxis is recommended for infants born at 32 weeks of gestation or earlier, until they reach 6 months of age, the elderly, persons with immunedeficiency and those in long term care facilities. Accordingly, the said composition or medicament is typically for use in preventing RSV infection in an infant less than 6 years of age, who was born after 32 weeks of gestation or less, the elderly, persons with immunosufficiency and those in long term care facilities. As described above, RSV strains upon exposure to fusion inhibitors known in the art rapidly develop resistance. In order to minimize the risk of development of resistance to fusion inhibitors it is desirable to combine them with another inhibitor of RSV replication with a different mode of action. To our knowledge, the benzodiazepine derivatives disclosed above are the first class of compounds with a novel mode of action. Accordingly, the compositions ofthe invention are characterized by a very low resistance profile, which makes them particularly suitable for therapeutic and prophylactic applications. The present invention also covers situations where components (a) and (b) are administered separately. Thus, for example, component (a) can be administered up to 24 hours before component (b). Alternatively, component (b) can be administered up to 24 hours before component (a). More usually, when components (a) and (b) are administered separately, they are administered within 12 hours, preferably within 6 hours, of each other. The present invention therefore also provides a product comprising (a) a said RSV fusion protein inhibitor and (b) a said benzodiazepine derivative for separate, simultaneous or sequential use in the treatment ofthe human or animal body. Typically, said product is for separate, simultaneous or sequential use in treating or preventing an RSV infection. Also provided is the use of a said RSV fusion protein inhibitor in the manufacture of a medicament for use in treating or preventing an RSV infection by co-administration with a said benzodiazepine derivative. The present invention also provides the use of a said benzodiazepine derivative in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a said RSV fusion protein inhibitor. When components (a) and (b) are administered separately, they are typically formulated as described above. The amount of active ingredient in each separate formulation will, of course, correspond to the amount of component (a) or (b) given above for the combined formulation. Thus, when components (a) and (b) are administered separately, a first formulation is typically provided which contains from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example about 2.5 wt%, of a said RSV fusion protein inhibitor, based on the total weight ofthe formulation. Similarly, a second formulation is typically provided which contains from 0.025 wt% to 10 wt%, preferably from 0.25 wt% to 5 wt%, more preferably from 1 wt% to 3.5 wt%, for example around 2.5 wt%, of a said benzodiazepine derivative, based on the total weight of the formulation. The two formulations can be administered separately in any order. Preferably, the compositions and medicaments ofthe invention have an activity greater than the combined individual activities of compounds (a) and (b). Thus, components (a) and (b) typically interact synergistically. Preferably, therefore, in the formulations and the medicaments ofthe invention, component (a) and component (b) are each present in an amount producing a synergistic therapeutic effect in treating or preventing an RSV infection. The anti-RSV compositions ofthe invention may be administered in a variety of dosage forms. Thus, they can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules. The compounds of the invention may also be administered parenterally, whether subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques. The compounds may also be administered as suppositories. In a preferred embodiment, administration is by intravenous, intranasal or intrabronchial means. In particular, formulations for treating or preventing RSV can advantageously be administered intranasally. The present invention therefore also provides an inhaler or nebuliser containing a medicament which comprises (i) a composition of the invention comprising component (a) and component (b), as defined above, and (ii) a pharmaceutically acceptable carrier or diluent. The anti-RSV compositions ofthe invention are typically formulated for administration with a pharmaceutically acceptable carrier or diluent. For example, solid oral forms may contain, together with the active compound(s), diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g. starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents, such as lecithin, polysorbates, laurylsulphates; and, in general, non toxic and pharmacologically inactive substances used in pharmaceutical formulations. Such pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar coating, or film coating processes. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol. The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride. Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. Preferably, the anti-RSV compositions ofthe invention are solubilised in a carrier containing (a) a pharmaceutically acceptable oil selected from esterification or polyether products of glycerides with vegetable oil fatty acids of chain length C8-Cιo and (b) a pharmaceutically acceptable surfactant selected from oleate and laurate esters of a polyalcohol copolymerized with ethylene oxide. Particularly preferred carriers contain Labrafil as the oil and Tween 20 or Tween 80 as the surfactant. The anti-RSV compositions ofthe invention also be suspended in PEG 400 for oral administration. A therapeutically effective amount of an anti-RSV composition ofthe invention is administered to a patient. A typical dose is from about 0.001 to 50 mg, typically 0.5 to 30 mg, preferably 1 to 20 mg active ingredient per kg of body weight, according to the activity of the specific composition, the age, weight and conditions ofthe subject to be treated, the type and severity ofthe disease and the frequency and route of administration. Preferably, daily dosage levels are from 5 mg to 2 g active ingredient. The following Examples illustrate the invention. They do not however, limit the invention in any way. In this regard, it is important to understand that the particular assays used in the Examples section are designed only to provide an indication of antiviral activity. There are many assays available to determine the activity of given compounds against RSV, and a negative result in any one particular assay is therefore not determinative. EXAMPLES
Example 1
3-[ 1 -(3 -Methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol- 1 - sulfonic acid dimethylamide, l-Methanesulfonyl-3-[l -(3 -methyl-butyl)- lH-benzoimidazol -2- ylmethyl] -1,3 -dihydro-benzoimidazol-2-one, 3 - [ 1 -(3 -Methyl-butyl)- 1 H-benzoimidazol-2- ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol-l-carboxylic acid benzylamide, 5-{3-[l-(3- Methanesulfonyl-propyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro-benzoimidazol- 1 -yl} -pentanenitrile, 7-[2-(3-Isopropenyl-2-oxo-2,3-dihydrobenzoimidazol- 1 -ylmethyl)- benzoimidazol- 1 -yl] -heptanenitril, 1 -Ethyl-3-[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2- ylmethyl]-l,3-dihydro-benzoimidazol-2-one, l-Ethyl-3-[l-(2-hydroxy-2-phenyl-ethyl)-lH- benzoimidazol-2-ylmethyl] -1,3 -dihydro-benzoimidazol-2-one, 1 -Isopropenyl-3 - [ 1 -(3 -oxo- butyl)-lH-benzoirnidazol-2-ylmethyl]-l,3-dihydro-benzoimidazol-2-one, l-(4-Hydroxy- benzyl)-3-[l-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro-benzoimidazol-2- one, l-Isopropenyl-3-[l-(3-methyl-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- benzoimidazol-2-one, 1 -Cyclopropyl-3-[l -(4-hydroxy-butyl)- lH-benzoimidazol-2- ylmethyl]- 1 ,3-dihydro-imidazo[4,5-c]pyridin-2-one and 1 -Isopropenyl-3-( 1 -propyl- 1 H- benzoimidazol-2-ylmethyl)-l,3-dihydro-imidazo[4,5-c]pyridine-2-one are prepared as described in WO00195910
Example 2
(2- 2-(L2-Dihydro-berizotriazol-l-ylmethyl)-berizoirnidazol-l-yl 1ethv -diethyl-amine is prepared as described in WO00004900.
Example 3
(2- 2-(3-Iodo-2.3-dihvdro-indazol-l-ylmethyl)-benzimidazol-l-yll-ethyl|-dimethyl-amine is prepared as described in WO03053344. Example 4
Bis(5-amidino-2-benzimidazolyl)-methane is prepared as described in US4,324794.
Example 5
2- (2-[ 1 - 1 -(2-Amino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol- 1 -ylmethyl} -6- methyl-p yridin-3 -ol is prepared as described in WO0100612.
Example 6
Compounds of general formula (V) are prepared as described in PCT/GB03/04050. In particular, (S)-l-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l ,4]benzodiazepin-3-yl-urea and (S)-4-methanesulfonyl-2-methoxy-N-(2-oxo-5- phenyl-2, 3 -dihydro- lH-benzore][l ,4]diazepin-3-yl)-benzamide were prepared according to the protocols described in Examples 75b and 73b of PCT/GB03/04050.
Example 7
Determination of RSV fusion inhibitor activity
RSV enters the host cell via attachment to and fusion with the host cell membrane. The effect of an inhibitor on the specific virus-cell fusion event can be qualitatively determined by using a fluorescence de-quenching system. The design of this assay takes advantage ofthe fact that RSV binds to cells at 4°C and at 37°C but that fusion may only occur at concentrations above 18°C. RSV labelled with octadecyl rhodamine dye (R18) is pre-incubated with Hep-2 cells seeded in a 6-well plate for 1 hour at 4°C to allow binding to occur. Unattached virus is removed by washing the cell monolayer. The inhibitor is then added to the virus-cell complexes prior to transferring the plates to 37°C for 1 hour in order to induce fusion. Virus-cell fusion can be observed directly under a fluorescence microscope. Fluorescence emission is quenched when 2 identical fluorophores are in close proximity. Upon fusion of the labelled virus with the cell membrane, the distance between fluorophores is increased due to dye spread and there is a decrease in quenching. This is observed as an increase in fluorescence intensity of R18. It therefore follows that inhibition of fusion would lead to a decrease in fluorescence of R18 compared to untreated control. Where the fluorescent yield of R18 in the presence of inhibitor is comparable to the untreated control this would suggest the inhibitor were not exerting its effects on the fusion protein.
Example 8
Determination of RSV replication inhibitor activity
The inner 60 wells of 96 well tissue culture plates are seeded with Hep-2 cells at 4xl04 cells/well for compound activity and toxicity studies in lOOμl of medium and incubated at 37°C overnight or until nearing confluency.
Cells are infected with 25 μl RSV, e.g. the RSS strain, previously titrated to give 80% cell kill. To each well 25μM of test compound are added. The final DMSO concentration is 0.5%. Some 200 μl of sterile distilled water is added to the outer wells ofthe plate and incubated at 37°C for 6 days. Some 0.25 μl/ml PMS are added to stock XTT solution, final cone. 25 μM PMS. Then 25 μl warmed XTT/PMS solution is added to each well and incubated for 1 hour at 37°C.
Maximum OD45onm reading (uninfected, untreated control cells) corresponds to 100% inhibition. Minimum OD450nm readings (infected control cells) corresponds to 0% inhibition. LoglO concentration is plotted against OD450nm and IC50 values are calculated from either reading 50% value from graph or using regression analysis.
Example 9 Synergistic action between RSV fusion inhibitor and anti-RSV benzodiazepines
ELISA experiments were carried out on the combined effect of potent benzodiazepine RSV replication inhibitor (S)-l-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-urea (compound A) with one RSV fusion inhibitor selected from l-cyclopropyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- imidazo[4,5-c]pyridin-2-one (compound B) or l-isopropenyl-3-(l -propyl- 1 H-benzoimidazol-
2-ylmethyl)-l,3-dihydro-imidazo[4,5-c]pyridine-2-one (compound B)
ELISA PROTOCOL
Mouse monoclonal antibodies to the phosphoprotein (P), nucleocapsid (N) & fusion (F) proteins of RSV and a rabbit anti-mouse- horseradwash peroxidase (HRP) conjugated secondary antibody were used to demonstrate a reduction in RSV antigen via conversion of the o-phenylene diamine dihydrochloride (OPD) substrate to a coloured product. This was quantified by optical density (OD) measurement.
Method
This assay was set up using all 96 wells of flat-bottomed 96-well plates. The outer wells were not subjected to any greater amount of evaporation than the inner wells during the 3 day assay period, (ie. No "edge effect" seen). Plates were set up one day before addition of virus and compounds. The assay then ran for 3 days with ELISA development taking place on the 4th day.
Day O Set up of Assay Plates
All 96 wells of a microtitre plate were seeded at a density of 5x103 Hep-2 cells/well in lOOμl/well of Growth Medium (GM) consisting of Dulbecco's MEM (DMEM) with
Glutamax-1, Sodium Pyruvate, 1000 mg 1 glucose and pyridoxine (Invitrogen, catalogue number 21885-025) and supplemented with 10%FBS. (See Plate 1). In tissue culture, the cells adhere to the tissue culture flask and were grown at 37°C, 5% CO2 until 90% confluent. Monolayers were washed with 20ml sterile PBS to remove serum and treated with 1ml trypsin to detach cells from the flask. Cells were suspended in a small known volume of growth media and counted using a haemocytometer. The cell suspension was made up to the desired concentration in growth medium and added to wells by multichannel pipette. Brief, gentle shaking encouraged the cells to disperse more evenly across the well.
Plate 1
Plates were kept undisturbed at 37°C in a 5% CO2 atmosphere for 24hrs during which time the cells settle to form an even cell monolayer.
Day l Addition of Virus A frozen vial of RSV (RSS strain provided by Virogen Ltd) stock solution was removed from the -80 freezer or liquid nitrogen store and diluted to a known Multiplicity of Infection (m.o.i) in Growth Medium. The m.o.i. was calculated by prior titration ofthe virus stock (by the ELISA assay method) as the virus input required to achieve a window of at least 0.8 OD units between infected and uninfected control wells.
Multiplicity of Infection = plaque forming units per well (pfu/well) number of cells per well 25μl (50μl in Example 9c) of diluted virus was added to infected wells by multichannel pipette; 25μl (50μl in Example 9c) of Growth Medium was added to uninfected, cell control wells by multichannel pipette.
Sides of plates were marked with stripes to identify plates in the event of lids becoming separated. Plates were incubated at 37°C for lhr to allow virus adsorption.
Compound Dilutions Compound "A" was titrated horizontally across the plate and Compound "B" was titrated vertically down the plate, creating a chequerboard. The 2 compounds were titrated at either Vi-log or doubling dilutions either across (horizontally) or down the plate (vertically) in the presence of virus. Each compound dilution was set up in duplicates or triplicates. For triplicates 3 identical plates were set up. Duplicates were set up as dublicate wells on the same plate. The dilution range covered concentrations from just above the compound IC50 to below the compound IC50 and included a OμM control for each compound.
Compounds were made up in a separate microtitre plate at 8x strength in GM containing 2% DMSO (a final DMSO concentration in the assay of 0.5%). 12.5μM (25μl in Example 9c) of the Compound "A" dilution series and 12.5μl (25μl in Example 9c) ofthe Compound "B" dilution series were then transfened to the appropriate wells ofthe assay plate by multichannel pipette, according to the marked out chequerboard.
12.5μl (25μl in Example 9c) of GM (containing 2% DMSO) was added to wells receiving OμM Compound "A" or OμM Compound "B". 25μl (50μl in Example 9c) GM (containing 2% DMSO) was added to wells containing neither compound.
Virus infected, untreated wells served as the virus control (VC); Uninfected, untreated wells serve as the cell control (CC). The difference in absorbance between CC and VC wells constitutes the assay window.
Plates were incubated at 37°C, 5% CO2 for 3 days. ELISA Stage
Day 4
Media was tapped out from wells directly into Virkon (1% solution in water) and plates were washed by immersing in a plastic box containing PBS.
50μl well of 75%/25% vol/vol acetone/methanol fixative was added by multichannel pipette and left for 3mins. Acetone/methanol was discarded from wells into Virkon and wells were washed with PBS as above.
Some 200μl of blocking solution (2% Marvel in PBS containing 0.05% Tween) was added per well by multichannel pipette. Plates were incubated at 37°C in a shaking incubator for 60mins.
Block solution was discarded down the sink and diluted primary antibody was added directly to wells (ie. no washing required).
RSV mouse monoclonal antibody NCL-RSV3 (Novocastra ) was diluted 1/400 in PBS/2% Marvel/0.05% Tween and 50μl was added per well. Plates were incubated at 37°C in a shaking incubator for 90mins.
Antibody was discarded down the sink and plates were washed 4 times by immersion in PBS/0.05% Tween. DAKo rabbit anti-mouse HRP conjugate (DAKO catalogue number P0260) was diluted
1/1000 in PBS/2% Marvel/0.05% Tween and 50μl was added per well. Plates were incubated at 37°C in a shaking incubator for 60mins.
Antibody was discarded down the sink and plates were washed 6 times by immersion in PBS/0.05% Tween. Substrate (SigmaFast OPD) was prepared in advance by dissolving 1 urea tablet in 20mL water. 1 OPD tablet was added to the urea solution just prior to use (NB. OPD was light sensitive) and vortexed to mix. 50μl of substrate was added per well.
The reaction was stopped by addition of 25μl/well of 20% sulphuric acid, once sufficient colour had developed but while cell control background was still low (~5 minutes).
Plates were read on a SpectraMax (Molecular Devices) spectrophotometer at wavelength 490nm and utilize the SOFTmax Pro software package.
The wells were emptied, washed in tap water and the monolayers stained with 50μl/well of 2% crystal violet in 20% methanol/water for at least 1 hour. The wells were then washed and air-dried and the monolayers examined under the microscope for indications of cell toxicity.
Results
SOFTmax data files were exported to Excel. Data handling used Excel templates written in- house for plotting dose response curves graphically and calculating IC50 values from the curves obtained.
All replicate wells were meaned. The assay window was calculated by subtracting the meaned cell control (CC) from the meaned virus control (VC). For each compound, the meaned CC was subtracted from the meaned values for each concentration point. The % of control was then calculated for each concentration point as a percentage ofthe window. % of control was plotted against compound concentration. A straight line was fitted to the curve and the slope and intercept functions were used to calculate the IC50.
The IC50 for Compound "A" was calculated for each background concentration of Compound "B". Similarly, the IC50 for Compound "B" was calculated for each background concentration of Compound "A".
Example 9a (S)-l-(2-Fluoro-phenyl)-3-f2-oxo-5-phenyl-2,3-dihydro-lH-benzo e1[ 41diazepin-3-yl)-urea (Compound B) in combination with the l-isopropenyl-3-π -propyl- 1 H-benzoimidazol-2- ylmethyl)-l,3-dihydro-imidazor4,5-c]pyridine-2-one (Compound A)
Compound B has an ELISA IC50 of 2μM against the RSV RSS strain. Compound A has an ELISA IC50 of 0.5μM against the RSV RSS strain.
In combination, at concentrations of Compound A below its IC50 (1, 0.3, 0.1 μM) the IC50 of Compound B is reduced from 0.5μM to at least 0.16μM (3.2-fold decrease). At concentrations of Compound B below its IC50 (0.3, 0.1 μM) the IC50 of Compound A is reduced from 2μM to at least 0.65μM (3-fold decrease).
Example 9b
(S)-l-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2-3-dihvdro-lH-benzo[el[1.41diazepin-3-yl)-urea (Compound B) in combination with l-cvclopropyl-3-ri-(4-hvdroxy-butyl)-lH- benzoimidazol-2-ylmethyll- 1 ■3-dihydro-imidazo 4,5-clpyridin-2-one (Compound A)
Compound B has an ELISA IC50 of 1.4μM against the RSV RSS strain. Compound A has an ELISA IC50 of 0.015μM against the RSV RSS strain.
In combination, at concentrations of Compound B below its IC50 (1, 0.3, 0.1, 0.03μM), the IC50 of Compound A is reduced from 0.015μM to at least 0.0007μM (21.4-fold decrease). At concentrations of Compound A below its IC50 (0.01, 0.003, 0.001, 0.0003μM) the IC50 of compound B is reduced from 1.4μM to at least 0.26μM (5.4-fold decrease).
Example 9c
(S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2.3-dihvdro-lH- benzo[e][1.41diazepin-3-yl)-benzamide (Compound A) in combination with l-cyclopropyl-3- T 1 -(4-hvdroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3-dihydro-imidazo 4.5-c]pyridin-2- one (Compound B) Compound A has an ELISA IC50 of lμM against the RSV RSS strain. Compound B has an ELISA IC50 of 0.08μM against the RSV RSS strain.
In combination, at concentrations of Compound A below its IC50 the IC50 of Compound B is reduced from 0.08μM to at least 0.03 μM (2.66-fold decrease). At concentrations of Compound B below its IC50 the IC50 of Compound A is reduced from lμM to at least 0.3μM (3.33-fold decrease).
The formula below can be used to identify a synergistic interaction.
FIC = Fractional Inhibitory concentration
Compares the activity of a compound in combination (Compound A + Compound B) with the activity ofthe compound alone (Compound A or Compound B).
FIC = Lowest IC50 Cud AC0MBINAT10N + Lowest IC50 Cpd B COMBINATION IC50 Cpd AALONE IC50 Cpd B^0
where FIC value < 0.5 SYNERGY 0.5 - 1.0 ADDITION 1.0 - 2.0 INDIFFERENCE >2.0 ANTAGONISM
FIC for (S)- 1 -(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3- yl)-urea in combination with the l-isopropenyl-3-(l-propyl-lH-benzoimidazol-2-ylmethyl)- 1 ,3-dihydro-imidazo[4,5-c]pyridine-2-one: <0.25 FIC for (S)- 1 -(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3- yl)-urea (Compound B) in combination with l-cyclopropyl-3-[l-(4-hydroxy-butyl)-lH- benzoimidazol-2-ylmethyl]-l,3-dihydro-imidazo[4,5-c]pyridin-2-one: <0.04
FIC for (S)-4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-benzamide in combination with l-cyclopropyl-3-[l-(4-hydroxy- butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro-imidazo[4,5-c]pyridin-2-one: 0.0675

Claims

1. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier or diluent and: (a) an inhibitor ofthe RSV fusion protein; and (b) a benzodiazepine derivative capable of inhibiting RSV replication.
2. A composition according to claim 1, wherein component (b) is a compound of formula (V), or a pharmaceutically acceptable salt thereof,
wherein: R represents Ci-6 alkyl, aryl or heteroaryl; R2 represents hydrogen or Cι.6 alkyl; each R3 is the same or different and represents halogen, hydroxy, Cι.6 alkyl, Cι-6 alkoxy, Cι.6 alkylthio, Ci-6 haloalkyl, Cι-6 haloalkoxy, amino, mono(Cι.6 alkyl)amino, di(Cι.6 alkyl)amino, nitro, cyano, -CO2R, -CONR7R77, -NH-CO-R7, -S(O)R , -S(O)2R7, -NH-S(O)2R, -S(O)NRR77 or -S(O)2NRR/7, wherein each R7 and R7 is the same or different and represents hydrogen or Cι-6 alkyl; n is from O to 3; R4 represents hydrogen or Cι-6 alkyl; R5 represents Cι-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι-6 alkyl)-, heteroaryl-(C ι-6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(Cι-6 alkyl)-, aryl-(Cι-6 hydroxyalkyl)-, heteroaryl -(Ci -6 hydroxyalkyl)-, carbocyclyl-(Cι-6 hydroxyalkyl)-, heterocyclyl-(Cι-6 hydroxyalkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)-, carbocyclyl-C(O)-C(O)-, heterocyclyl-C(O)-C(O)- or -XR6; X represents -CO-, -S(O)- or -S(O)2-; and R6 represents Cι-6 alkyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι-6 alkyl)-, heteroaryl-(Cι-6 alkyl)-, carbocyclyl-(Cι.6 alkyl)-, heterocyclyl-(Cι.6 alkyl)-, aryl-(Cι-6alkyl)-O-, heteroaryl-(Cι-6 alkyl)-O-, carbocyclyl-(Cι-6 alkyl)-O-, heterocyclyl-(Cι-6 alkyl)-O- or -NRR wherein each R and R7 is the same or different and represents hydrogen, Cι-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(Cι-6 alkyl)-, heteroaryl-(Cι-6 alkyl)-, carbocyclyl - (Cι-6 alkyl)- or heterocyclyl-(Cι-6 alkyl)-.
3. A composition according to claim 2 wherein: each R is the same or different and represents halogen, hydroxy, Cι-6 alkyl, Cι-6 alkoxy, Cι-6 alkylthio, Ci-6 haloalkyl, Cι-6 haloalkoxy, amino, mono(Cι-6 alkyl)amino, di(Cι-6 alkyl)amino, nitro, cyano, -CO2R7, -CONR7R/, -NH-CO-R7, -S(O)R7, -S(O)2R7, -NH-S(O)2R or -S(O)NRR77, wherein each R and R77 is the same or different and represents hydrogen or Cι-6 alkyl; R represents Cι-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι.6 alkyl)-, heteroaryl-(Cι-6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(Cι-6 alkyl)- or -XR6; X represents -CO-, -S(O)- or -S(O)2-; and R6 represents Cι-6 alkyl, hydroxy, Ci-6 alkoxy, Ci-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(Cι-6 alkyl)-, heteroaryl-(Ci-6 alkyl)-, carbocyclyl-(Cι-6 alkyl)-, heterocyclyl-(Cι-6 alkyl)- or -NRR77 wherein each R7 and R7 is the same or different and represents hydrogen, Cι-6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, aryl-(Cι-6 alkyl)- or heteroaryl-(Cι.6 alkyl)-.
4. A composition according to either claim 2 or claim 3, wherein R1 is C1-2 alkyl or aryl.
5. A composition according to any one of claims 2 to 4 wherein R2 is hydrogen.
6. A composition according to any one of claims 2 to 5 wherein R3 is halogen, hydroxy, CM alkyl, CM alkoxy, CM alkylthio, CM haloalkyl, CM haloalkoxy, amino, mono(CM alkyl)amino or di(CM alkyl)amino.
7. A composition according to claim 6, wherein R is fluorine, chlorine, bromine, C1-2 alkyl, C1-2 alkoxy, C1-2 alkylthio, C1-2 haloalkyl, C1.2 haloalkoxy, amino, mono(Cι-2 alkyl)amino or di (C1-2 alkyl)amino.
8. A composition according to any one of claims 2 to 7 wherein R4 is hydrogen or Cι.2 alkyl.
9. A composition according to any one of claims 2 to 8 wherein R5 is Cι-6 alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(CM alkyl)-, aryl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6.
10. A composition according to claim 9, wherein R5 is CM alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl, phenyl-(Cι-2 alkyl)-, heteroaryl-(Cι-2 alkyl)-, phenyl-C(O)-C(O)-, heteroaryl-C(O)-C(O)- or -XR6.
11. A composition according to claim 10, wherein R5 is CM alkyl, phenyl, thienyl, furanyl, isoxazolyl, pyridyl, cyclopentyl, cyclohexyl, benzothienyl, dihydrobenzofuranyl, phenyl-CH2-, furanyl-CH2-, phenyl-C(O)-C(O)-, thienyl-C(O)-C(O)- or -XR6.
12. A composition according to any one of claims 2 to 11 wherein X is -CO- or -S(O)2-.
13. A composition according to any one of claims 2 to 12 wherein, when R6 is a group NRR77 wherein each R7 and R77 is the same or different and represents hydrogen, CM alkyl, aryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)- or heteroaryl-(CM alkyl)-.
14. A composition according to claim 13, wherein when R6 is a group -NR7R77 each R7 and R77 is the same or different and represents hydrogen, CM alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-CH2-.
15. A composition according to claim 14, wherein when R6 is a group -NRR77 and one of R7 and R7 is hydrogen.
16. A composition according to any one of claims 2 to 15 wherein R is Cι-6 alkyl, hydroxy, Cι-6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocyclyl, aryl-(CM alkyl)-, heteroaryl-(CM alkyl)-, carbocyclyl-(CM alkyl)-, heterocyclyl-(Cι-4 alkyl)-, aryl-(Cι.4 hydroxyalkyl)-, heteroaryl-(CM hydroxyalkyl)-, carbocyclyl-(CM hydroxyalkyl)-, heterocyclyl-(CM hydroxyalkyl)-, aryl-(CM alkyl)-O-, heteroaryl-(CM alkyl)-O-, carbocyclyl-(C alkyl)-O-, heterocyclyl-(CMalkyl)-O- or -NRR77.
17. A composition according to claim 16, wherein R6 is Ci-ό alkyl, Cι-6 alkoxy, Cι-6 alkylthio, aryl, heteroaryl, carbocyclyl, heterocycly, phenyl-(Cι-2 alkyl)-, phenyl-(Cι-2 alkyl)- O-, heteroaryl-(Cι-2 alkyl)-, phenyl-(C 1-2 hydroxyalkyl)-, heteroaryl-(Cι-2 hydroxyalkyl)- or
-NRR77.
18. A composition according to claim 17, wherein R6 is CM alkyl, CM alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(Cι-2 alkyl)-, phenyl-CH2-CH(OH)-, phenyl- CH(OH)-CH2-, phenyl-(Cι-2 alkyl)-O-, lH-benzo[d]imidazol-2(3H)-onyl or -NRR .
19. A composition according to any one ofthe claims 2 to 18 wherein the benzodiazepine derivative of formula (V) is a benzodiazepine derivative of formula (Va):
wherein: R1 is phenyl or methyl; R3 is methyl or chlorine; n is 0 or 1 ; R4 is hydrogen or methyl; - R5 is phenyl-CH2-, furanyl-CH2-, thienyl-C(O)-C(O)- or -XR6; X is -CO- or -S(O)2-; and R6 is CM alkyl, CM alkoxy, phenyl, naphthyl, dihydrobenzofuranyl, benzodioxinyl, 9H-fluoren-9-onyl, indolyl, thienyl, furanyl, oxazolyl, isoxazolyl, pyrazolyl, pyridyl, benzothienyl, benzofuranyl, cyclopentyl, cyclohexyl, piperazinyl, piperidinyl, morpholinyl, phenyl-(Cι-2 alkyl)-, phenyl-CH2-CH(OH)-phenyl-CH(OH)-CH2-, phenyl-(Cι-2 alkyl)-O-, lH-benzo[d]imidazol-2(3H)-onyl or -NRR/7 wherein each R7 and R77 is the same or different and represents hydrogen, CM alkyl, phenyl, thienyl, cyclohexyl, cyclopentyl or phenyl-(CH2)-, the phenyl moiety in the group R1 being unsubstituted or substituted by a single fluorine, chlorine, Cι-2 alkyl, C1-2 alkoxy, Cι-2 alkylthio, C1.2 haloalkyl or C1.2 haloalkoxy substituent; the aryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1 ,2 or 3 substituents selected from fluorine, chlorine, bromine, iodine, CM alkyl, C2 acyl, hydroxy, Cι-4 alkoxy, CM alkylthio, CM haloalkyl, Cι-4 haloalkoxy, amino, mono(Cι-4 alkyl)amino, di(C alkyl)amino, nitro, -CO2R7, -S(O)2R7 and -S(O)2NH2, wherein R7 represents C1-2 alkyl; the heteroaryl moieties in the groups R5 and R6 being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine, C1-2 alkyl, C1-2 haloalkyl and di(Ci-2 alkyl)amino; and the heterocyclyl and carbocyclyl moieties in the R6 group being unsubstituted or substituted by 1 or 2 substituents selected from fluorine, chlorine, bromine,Cι-4 alkyl, CM alkoxy, CM haloalkyl and nitro.
20. A composition according to claim 1, wherein the benzodiazepine derivative of formula (V) is: Cyclohexanecarboxylic acid 2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; 3-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; 4-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Methoxy N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-trifluoromethyl- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; Thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-3-amide; Furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 - yl)-amide; Piperidine-1 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)-amide; Morpholine-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4] diazepin-3 -yl)-amide ; 4-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 3-Nitro- N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 4-Methyl-piperazine-l -carboxylic acid -(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; 3,4-Dichloro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l)4]diazepin-3-yl)-2-trifluoromethyl- benzamide; 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Methyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Chloro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-benzamide; 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; (S)-2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)-benzamide Benzo[b]thiophene-3-carboxylic acid (2 -oxo-5-phenyl-2,3 -dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-amide; 2,3-Dihydro-benzofuran-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl)-amide; Isoxazole-5-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-amide; Benzo[b]thiophene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [l,4]diazepin-3-yl)-amide; Thiophen-3-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-amide; N-(2-Oxo-5 -phenyl-2 , 3 -dihydro- 1 H-benzo [e] [1,4] diazepin-3 -yl)-isonicotinamide; N-(2-Oxo-5 -phenyl-2 , 3 -dihydro- 1 H-benzo [e] [1,4] diazepin-3 -yl)-nicotinamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)- methanesulfonamide; Propane- 1 -sulfonic acid-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 - yl)-amide; Butane- 1-sulfonic acid~(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-amide; 2-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 3-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 4-Bromo-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzenesulfonamide; 3-(2-Nitro-benzylamino)-5-phenyl- 1 ,3-dihydro-benzo[e] [ 1 ,4]diazepin-2-one; 3-(3-Nitro-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 3-(4-Nitro-benzylamino)-5-phenyl- 1 ,3-dihydro-benzo[e] [ 1 ,4]diazepin-2-one; 3 -(2-Methoxy-benzylamino)-5-phenyl- 1 ,3 -dihydro-benzo[e] [ 1 ,4]diazepin-2-one; 3-(3-Methoxy-benzylamino)-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; 5-Phenyl-3-(2-trifluoromethyl-benzylamino)-l,3-dihydro-benzo[e][l,4]diazepin-2- one; 5-Phenyl-3-(3-trifluoromethyl-benzylamino)- 1 ,3-dihydro-benzo[e] [ 1 ,4]diazepin-2- one; 5-Phenyl-3-(4-trifluoromethyl-benzylamino)-l,3-dihydro-benzo[e][l,4]diazepin-2- one; 3-[(Furan-2-ylmethyl)-amino]-5-phenyl-l,3-dihydro-benzo[e][l,4]diazepin-2-one; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-acetamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- isobutyramide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- methanesulfonamide ; Furan-2 -carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4] diazepin-3-yl)-amide; Thiophene-2-carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[1 ,4]diazepin-3-yl)-amide; Cyclohexanecarboxylic acid (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1 ,4]diazepin-3-yl)-amide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-2- methoxy-benzamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-4- methoxy-benzamide; N-(7-Chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-nitro- benzamide; 2-(2-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(3-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(4-Methoxy-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-acetamide; 2-(4-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- acetamide; 2-(3-Nitro-phenyl)N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazeρin-3-yl)-2-(2- trifluoromethyl-phenyl)-acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(3- trifluoromethyl-phenyl)-acetamide; N-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-2-(4- trifluoromethyl-phenyl)-acetamide; l-(2-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-urea; l-(2-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; 1 -(2-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [1 ,4]diazepin-3-yl)- urea; 1 -(4-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3-p-tolyl-urea; 1 -(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(4-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3 -yl)- urea; (S)-l-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[1 ,4]diazepin-3-yl)-benzamide; (S)- 4-Methanesulfonyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-benzamide; 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e][ 1 ,4]diazepin-3-yl)- benzamide; (S)- 5-Acetyl-2-ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; 6-Fluoro-4H-benzo[l ,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo [e] [ 1 ,4]diazepin-3-yl)-amide; (S)- 6-Fluoro-4H-benzo[l,3]dioxine-8-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-amide; (S)-2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-4- trifluoromethyl-benzamide; 2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (S)-2,4,5-Trifluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (S)-2-Hydroxy- N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; lH-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-amide ; (S)-lH-Indole-7-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [l,4]diazepin-3-yl)-amide; 3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; (S)-3-Methoxy-naphthalene-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; N-[7-Chloro-5-(2-fluoro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4]diazepine-3- yl]-4-methoxoy-benzamide; 1 -(2-Fluoro-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; 1 -(4-Methoxy-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro- lH-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; 1 -(3-Methyl-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(4-trifluoromethyl- phenyl)-urea; 4-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-benzamide; 4-Methoxy-3-nitro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3- yl)benzamide; 3-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 5-Chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)benzamide; 5-Fluoro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 5-Methoxy-2-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 3-Methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 3-(2-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)propionamide; 3-(3-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-propionamide; 3-(4-Methoxy-phenyl)-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yι)-propionamide; N-[5-(3-Chloro-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]-2- methoxy-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- 4-methoxy-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]-
2-nitro-benzamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- 4-nitro-benzamide; 4-Methoxy-N-[2-oxo-5-(4-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [l,4]diazepin-3-yl]-benzamide; 2-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [1 ,4]diazepin-3-yl]-benzamide; 4-Methoxy-N-[2-oxo-5-(3-trifluoromethyl-phenyl)-2,3-dihydro-lH-benzo[e] [1 ,4]diazepin-3-yl]-benzamide; 2-Ethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3 -yl)- benzamide; 2,4-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 2-Bromo-5-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-benzamide; 2-Methoxy-N-[5-(3-mehtoxy-phenyl)-2-oxo-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl]-benzamide N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl]-4-nitro-benzamide; 2-Methoxy-N-(8-methyl-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)-benzamide; 2-Chloro-4-methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; 2-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; (2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-carbamic acid benzyl ester; l-(3,5-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(4- trifluoromethoxy-phenyl)-urea; 1 -(4-Bromo-2-trifluoromethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl)-urea; l-(4-Bromo-benzyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; l-(2,3-Dichloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3 -yl)-urea; 1 -(2,6-Dimethyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; l-(2-Chloro-6-methyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[ 1 ,4]diazepin-3-yl)-urea; 1 -(4-Nitro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- urea; l-(2-Methylsulfanyl-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; l-(2,6-Dichloro-phenyl)-3-(2-oxo-5-ρhenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; 5-tert-Butyl-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; 2,5-Dimethoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; 1 -(2,6-Difluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-urea; l-(3-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; l-(3-Methoxy-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-(3-trifluoromethyl- phenyl)-urea; l-(3-Chloro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- urea; 2-Methoxy-4-methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-benzamide; 4-Methanesulfonyl-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)terephthalamic acid methyl ester; 2-Fluoro-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 2,6-Difluoro-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- benzamide; N-(2-Oxo-5 -phenyl-2, 3 -dihydro- 1 H-benzo [e] [ 1 ,4] diazepin-3 -yl)-2-propoxy- benzamide; 2-Iodo-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-benzamide; 3-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- terephthalamic acid methyl ester; 4-Amino-5-chloro-2-methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[ 1 ,4]diazepin-3-yl)-benzamide; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-m-tolyl-urea; 2-Methylsulfanyl-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)- benzamide; 2-Methoxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-5- sulfamoyl-benzamide; 2-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3- phenyl-propionamide 3-Hydroxy-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3- phenyl-propionamide ; 3-(2-Fluoro-phenyl)-l -methyl- 1 -(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3 -yl)-urea; 2-Methoxy-N-methyl-4-nitro-N-(2-oxo-5-phenyl-2,3 -dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-benzamide; l-tert-Butyl-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-urea; 1 -Cycloheyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; 1 -Ethyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; 1 -Butyl-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-urea; 4,5-Dimethyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [1 ,4]diazepin-3-yl)amide; Piperidine-1 -carboxylic acid (7-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[1 ,4]diazepin-3-yl)-amide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl)acetamide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl]- isobutyramide; Furan-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl]-amide; Thiophene-2-carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; Cyclohexanecarboxylic acid [5-(3chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; Piperidine-1 -carboxylic acid [5-(3-chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl]-amide; N-[5-(3-Chloro-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3- yl]isonicotinamide; 5-Methyl-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4] diazepin-3-yl)-amide; Pyrazine-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-amide; N-[5-(3-Methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl]-isobutyr amide; Thiophene-2-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo [e] [1,4] diazepin-3 -yl] -amide ; Cyclohexanecarboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl]-amide; Piperidine- 1 -carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo [e] [ 1 ,4] diazepin-3 -yl] -amide; Piperidine-4-carboxylic acid [5-(3-methoxy-phenyl)-2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl]-amide; Cyclohexanecarboxylic acid (8-chloro-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [l,4]diazepin-3-yl)-amide; Thiophene-2-carboxylic acid (8-methyl-2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; l-(2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-3-thiophene-2-yl- urea; 1 -(2-Oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-3-thiophene-3-yl- urea; Pyridine-2 -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4] diazepin-3-yl)-amide; 1 H-Pyrazole-4-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-l H-benzo[e] [ 1 ,4] diazepin-3 -yl)-amide; 6-Dimethylamino-N-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)- nicotinamide; 2-Ethoxy-naphthalene-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l,4]diazepin-3-yl)-amide; 9-Oxo-9H-fluorene-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e]
[l,4]diazepin-3-yl)-amide; 2-Oxo-2,3-dihydro-benzoimidazole-l -carboxylic acid (2-oxo-5-phenyl-2,3-dihydro- lH-benzo[e][l,4]diazepin-3-yl)-amide; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)carbamic acid tert-butyl ester; (S)-4,5-Dibromo-furan-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH- benzo [e] [ 1 ,4]diazepin-3 -yl)-amide; (S)-Benzofuran-2-carboxylic acid (2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e] [ 1 ,4]diazepin-3-yl)-amide; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid methyl ester; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4]diazepin-3-yl)-carbamic acid ethyl ester; (2-Oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4]diazepin-3-yl)-carbamic acid isobutyl ester; and 2-Oxo-N-(2-oxo-5-phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3-yl)-2-thiophene- 2-yl-acetamide.
21. A composition according to any one of claims 2 to 20, wherein the benzodiazepine derivative of formula (V) is 1 -(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro- 1 H- benzo[e][l,4]diazepin-3-yl)-urea, 2-methoxy-4-nitro-N-(2-oxo-5-phenyl-2,3-dihydro-lH- benzo[e][l ,4]diazepin-3-yl)-benzamide or 4-methanesulfonyl-2-methoxy-N-(2-oxo-5- phenyl-2,3-dihydro- 1 H-benzo[e] [ 1 ,4]diazepin-3 -yl)-benzamide.
22. A composition according to claim 21 , wherein the benzodiazepine derivative of formula (V) is l-(2-fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l,4] diazepin-3-yl)-urea.
23. A composition according to any one ofthe preceding claims wherein component (a) is a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein:
X is a direct link or Cι-6 alkyl; said Cι.6 alkyl being optionally substituted with halogen, oxo, cyano, hydroxyl, OCOR** or S(O)n-Cι-6 alkyl; Y is R4, NR4R5, NCOR4, =^01^, -CONHI^, COOR4, -OR4, aryl, heteroaryl, cyclyl or heterocyclyl, where RA and R5 are H or Cι-6 alkyl; Z is CRδRγ, where Re and R7 are independently H, or straight, branched or cyclic Cι-6 alkyl; n is 1-2; Ri is CONI^Rs, CO2 i or Cι-6 alkyl, said Cι-6 alkyl can be optionally substituted with ORA or NRsR9; Rs and R9 are each independently H, Cι.6 alkyl, SO2 5, CO2R or CORj; R2 is selected from the group consisting of NH2, CONRδR7, heteroaryl, C2-6 alkenyl, CO2 J, N=CPh2, C(=NH)NH2 and Cι-6 alkyl; said alkyl optionally substituted with a member selected from the group consisting of halogen, CN, NR10R11, OSO2 1 and OR,; Rio and Rn are each independently selected from the group consisting of H, Cι-6 alkyl, C3-6 cycloalkyl, CO2R4, COR4 and SO2R4; R3 is selected from the group consisting of (1) CO2R9; (2) Cι.6 alkyl optionally substituted with CN, OR» or NRβR7; and (3) C2-6 alkenyl substituted with CN; Q is a member selected from the group consisting of
A is C or N, optionally substituted with H, halogen, Cι-6 alkyl, C2-6 alkenyl, cyano-Ci- 6 alkyl, CO∑R^ aryl, benzoaminocarbonyl, hydroxybenzyl, SO2NR4R5 or C .6 cycloalkyl. Where A is carbon, it may also be optionally substituted by O or S via a double bond; B is C or N; where B is C it may be optionally substituted by H, Cι-6 alkyl, NO2, CN, halogen, COR4, COOR^ CONHR4C(=NH)NH2 or C(=NOH)NH2.
24. A composition according to any of claims 1 to 22, wherein component (a) is a compound ofthe formula (I), as defined above or a pharmaceutically acceptable salt thereof, wherein at least two of Ri, R2 and R are hydrogen, and the other is hydrogen or -C(NH)- NH2 and/or either -X-Y is H, or X is a Cι-C6 alkylene group which is unsubstituted or substituted by a hydroxy group and Y is H, OH, CN, -NR7R77, -COR7, -SO2R7 or phenyl, wherein R7 and R7 are the same or different and represent a Cι-C4 alkyl group and/or Z is - CH2- and/or Q is a moiety
wherein B is -CH- or -N-, Ai is -C(O)- or -NH- and A2 is -CH2-, -CHR- or -NR7 -, wherein R7 is a halogen atom and R77 represents a hydrogen atom or a Cι-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, -SO2-(Cι-C6 alkyl), -SO2-N(Cι-C6 alkyl)2 or -(CO-NH)a-(Cι-C4 alkyl)-phenyl group, wherein a is 0 or 1, which group is unsubstituted or is substituted with a hydroxy or cyano substituent.
25. A composition according to any of claims 1 to 22, wherein component (a) is a compound of the formula (II), or a pharmaceutically acceptable salt thereof
wherein: each X is the same or different and is CH or N; each Ri is the same or different and is Cι-6 alkyl, halogen, hydroxy, phenyl or (CH2)m=NH2; n is 1 or 2; R2 is Ci-6 alkoxy or Cι-6alkoxy-phenyl; R3 is Cι-6alkyl; L2 is -CH2- or -NH-; Y is C 1-6 alkyl or Cι-6 alkenyl; Z is H, N(R4)2-, -C(=O)-R5, -C(=CH2)-R5, -CH(OH)-R5, -CH(CH3)-R5, -CH(OCH3)- R5; each RA is the same or different and is H, Ci-6 alkyl. R5 is C 1-6 alkyl-carbonyl, amino, hydroxyl, aryl, heteroaryl, carbocyclyl, heterocyclyl; and m=l-6
26. A composition according to anyone of claims 1 to 22, wherein component (a) is: l-Cyclopropyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- imidazo[4, 5 -c]pyridin-2-one {2-[2-(l ,2-Dihydro-benzotriazol-l -ylmethyl)-benzoimidazol-l -yl]]ethyl} -diethyl- amine {2-[2-(3-Iodo-2,3-dihydro-indazol-l -ylmethyl)-benzimidazol- 1 -yl]-ethyl} -dimethyl- amine 1 -Isopropenyl-3-[ 1 -(3-methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl]-l ,3-dihydro- benzoimidazol-2-one 1 -(4-Hydroxy-benzyl)-3-[ 1 -(3-methyl-butyl)-l H-benzoimidazol-2-ylmethyl]- 1 ,3- dihydro-benzoimidazol-2-one l-Isopropenyl-3-[l-(3-oxo-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- benzoimidazol-2-one l-Ethyl-3-[l-(2-hydroxy-2-phenyl-ethyl)-lH-benzoimidazol-2-ylmethyl]-l,3- dihydro-benzoimidazol-2-one l-Ethyl-3-[l-(4-hydroxy-butyl)-lH-benzoimidazol-2-ylmethyl]-l,3-dihydro- benzoimidazol-2-one 7-[2-(3-Isopropenyl-2-oxo-2,3-dihydroberιzoimidazol-l-ylmethyl)-benzoirnidazol-l- yl]-heptanenitril 5-{3-[l-(3-Methanesulfonyl-propyl)-lH-benzoimidazol-2-ylmethyl]-2-oxo-2,3- dihydro-benzoimidazol- 1 -yl} -pentanenitrile 3 - [ 1 -(3 -Methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl] -2-oxo-2 , 3 -dihydro- benzoimidazol-1 -carboxylic acid benzylamide 1 -Methanesulfonyl-3-[l -(3-methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3- dihydro-benzoimidazol-2 -one 3-[ 1 -(3-Methyl-butyl)- 1 H-benzoimidazol-2-ylmethyl]-2-oxo-2,3-dihydro- benzoimidazol- 1-sulfonic acid dimethylamide l-Isopropenyl-3-(l-propyl-lH-benzoimidazol-2-ylmethyl)-l,3-dihydro-imidazo[4,5- c]pyridine-2-one Bis(5-amidino-2-benzimidazolyl)-methane 2- {2-[ 1 -[ 1 -(2-A-rnino-ethyl)-piperidin-4-ylamino]-4-methyl-benzoimidazol- 1 - ylmethyl}-6-methyl-pyridin-3-ol or a pharmaceutically acceptable salt thereof.
27. A composition according to any one of claims 1 to 22, wherein component (a) is 1- cyclopropyl-3 -[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl] - 1 ,3 -dihydro- imidazo[4,5-c]pyridin-2-one, {2-[2-( 1 ,2-dihydro-benzotriazol- 1 -ylmethyl)-benzoimidazol- 1 - yl] ] ethyl }-diethyl-amine, {2-[2-(3-iodo-2,3-dihydro-indazol-l-ylmethyl)-benzimidazol-l-yl]- ethyl }-dimethyl-amine or a pharmaceutically acceptable salt thereof.
28. A composition according to any one of claims 1 to 22, wherein component (a) is 1- cyclopropyl-3-[ 1 -(4-hydroxy-butyl)- 1 H-benzoimidazol-2-ylmethyl]- 1 ,3-dihydro- imidazo[4,5-c]pyridin-2-one or l-Isopropenyl-3-(l-propyl-lH-benzoimidazol-2-ylmethyl)- 1 ,3-dihydro-imidazo[4,5-c]pyridine-2-one or a pharmaceutically acceptable salt thereof.
29. A composition according to any one ofthe preceding claims wherein component (a) is present in an amount of from 0.025 wt% to 10 wt%.
30. A composition according to any one of the preceding claims wherein component (b) is present in an amount of 0.025 wt% to 10 wt%.
31. A composition according to any one ofthe preceding claims, for use in the treatment ofthe human or animal body.
32. Use of: (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and (b) a benzodiazepine derivative defined in any one of claims 1 to 22, in the manufacture of a medicament for use in treating or preventing an RSV infection.
33. Use according to claim 31 , wherein the medicament is a composition as defined in claim 29 or 30.
34. A product comprising: (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and (b) a benzodiazepine derivative as defined in any one of claims 1 to 22; for separate, simultaneous or sequential use in the treatment ofthe human or animal body.
35. A product according to claim 34 for separate, simultaneous or sequential use in treating or preventing an RSV infection.
36. A method of treating or preventing an RSV infection in a patient, which method comprises the administration to said patient of: (a) an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28; and (b) a benzodiazepine derivative as defined in any one of claims 1 to 22.
37. Use of an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co-administration with a benzodiazepine derivative as defined in any one of claims 1 to 22.
38. Use of a benzodiazepine derivative as defined in any one of claims 1 to 22, in the manufacture of a medicament for use in treating or preventing an RSV infection, by co- administration with an RSV fusion protein inhibitor as defined in any one of claims 1 and 21 to 28.
EP05718061A 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein Not-in-force EP1727550B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL05718061T PL1727550T3 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein
CY20091101108T CY1109523T1 (en) 2004-03-19 2009-10-26 PHARMACEUTICAL COMPOSITION comprising a benzodiazepine derivative and an RSV Fusion Inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406282.4A GB0406282D0 (en) 2004-03-19 2004-03-19 Therapeutic compounds
PCT/GB2005/001018 WO2005089769A1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the rsv fusion protein

Publications (2)

Publication Number Publication Date
EP1727550A1 true EP1727550A1 (en) 2006-12-06
EP1727550B1 EP1727550B1 (en) 2009-07-29

Family

ID=32118068

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05718061A Not-in-force EP1727550B1 (en) 2004-03-19 2005-03-18 Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein

Country Status (19)

Country Link
US (1) US8853204B2 (en)
EP (1) EP1727550B1 (en)
JP (1) JP4940128B2 (en)
KR (2) KR20130042593A (en)
CN (1) CN1933842A (en)
AT (1) ATE437643T1 (en)
AU (2) AU2005224157B2 (en)
BR (1) BRPI0507654A (en)
CA (1) CA2558112C (en)
CY (1) CY1109523T1 (en)
DE (1) DE602005015686D1 (en)
DK (1) DK1727550T3 (en)
ES (1) ES2327757T3 (en)
GB (1) GB0406282D0 (en)
HK (1) HK1098372A1 (en)
PL (1) PL1727550T3 (en)
PT (1) PT1727550E (en)
RU (1) RU2388476C2 (en)
WO (1) WO2005089769A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds
KR20090087079A (en) * 2006-11-21 2009-08-14 노파르티스 아게 Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
GB201506448D0 (en) 2015-04-16 2015-06-03 Univ Durham An antimicrobial compound
AU2016297024B2 (en) 2015-07-22 2021-03-04 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
EP3402799B1 (en) 2016-01-15 2022-05-04 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
GB201613942D0 (en) 2016-08-15 2016-09-28 Univ Of Durham The An antimicrobial compound
US10398706B2 (en) 2017-01-06 2019-09-03 Enanta Pharmaceuticals, Inc. Heteroaryldiazepine derivatives as RSV inhibitors
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2019067864A1 (en) * 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as rsv inhibitors
CA3080138A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
WO2019094920A1 (en) * 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
MX2021011144A (en) 2019-03-18 2022-01-18 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors.
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
GB201911944D0 (en) 2019-08-20 2019-10-02 Reviral Ltd Pharmaceutical compounds
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
MX2022003984A (en) 2019-10-04 2022-07-27 Enanta Pharm Inc Antiviral heterocyclic compounds.
GB201915273D0 (en) * 2019-10-22 2019-12-04 Reviral Ltd Pharmaceutical compounds
UY39032A (en) 2020-01-24 2021-07-30 Enanta Pharm Inc HETEROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
US11945824B2 (en) 2020-10-19 2024-04-02 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US11945830B2 (en) 2021-02-26 2024-04-02 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
US12080039B2 (en) 2021-06-08 2024-09-03 Kyndryl, Inc. Contextual policy-based computer vision control

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324794A (en) * 1980-08-26 1982-04-13 Research Triangle Institute Inhibition of respiratory syncytial virus-induced cell fusion by amidino compounds
EP0491218A1 (en) * 1990-12-17 1992-06-24 F. Hoffmann-La Roche Ag Benzodiazepinones
CN1251579A (en) * 1997-04-07 2000-04-26 Axys药物公司 Compound and compositions for treating diseases associated with serine protease, particularly tryptase, activity
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
AU2002351255A1 (en) * 2001-12-10 2003-06-23 Bristol-Myers Squibb Company Bis hydrochloride monohydrate salt of rsv fusion inhibitor
US6919331B2 (en) * 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
JP2004107494A (en) * 2002-09-18 2004-04-08 National Institute For Materials Science Thermoplastic lamellar alkylsiloxane and its manufacturing process
JP4719466B2 (en) * 2002-09-20 2011-07-06 アロー セラピューティクス リミテッド Benzodiazepine derivatives and pharmaceutical compositions containing them
GB0406279D0 (en) * 2004-03-19 2004-04-21 Arrow Therapeutics Ltd Therapeutic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005089769A1 *

Also Published As

Publication number Publication date
GB0406282D0 (en) 2004-04-21
ES2327757T3 (en) 2009-11-03
ATE437643T1 (en) 2009-08-15
PL1727550T3 (en) 2010-01-29
AU2005224157A1 (en) 2005-09-29
RU2006136880A (en) 2008-04-27
PT1727550E (en) 2009-08-28
AU2005224157B2 (en) 2009-05-28
JP2007529489A (en) 2007-10-25
BRPI0507654A (en) 2007-07-10
AU2009212826A1 (en) 2009-09-17
WO2005089769A1 (en) 2005-09-29
EP1727550B1 (en) 2009-07-29
KR20070009629A (en) 2007-01-18
DE602005015686D1 (en) 2009-09-10
CA2558112A1 (en) 2005-09-29
DK1727550T3 (en) 2009-10-19
CY1109523T1 (en) 2014-08-13
CA2558112C (en) 2014-07-29
KR20130042593A (en) 2013-04-26
US8853204B2 (en) 2014-10-07
KR101292431B1 (en) 2013-07-31
US20070142403A1 (en) 2007-06-21
RU2388476C2 (en) 2010-05-10
JP4940128B2 (en) 2012-05-30
CN1933842A (en) 2007-03-21
HK1098372A1 (en) 2007-07-20

Similar Documents

Publication Publication Date Title
US8853204B2 (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein
EP1727551B1 (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein
AU2006203946B2 (en) Compositions and methods relating to novel compounds and targets thereof
JP5298103B2 (en) Benzodiazepine derivatives and pharmaceutical compositions containing them
AU2005323519B2 (en) Methods and compositions for treating diseases and conditions associated with mitochondrial function
AU2005282461C1 (en) Compositions and methods relating to novel compounds and targets thereof
US20060052369A1 (en) Compositions and methods relating to novel compounds and targets thereof
CA2557929A1 (en) Benzodiazepines for treating or preventing or preventing rsv infection
MXPA06010711A (en) Pharmaceutical composition comprising a benzodiazepine derivative and an inhibit or of the rsv fusion protein
MXPA06010709A (en) Pharmaceutical composition comprising a benzodiazepine derivative and a inhibitor of the rsv fusion protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061019

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

111Z Information provided on other rights and legal means of execution

Free format text: ATBEBGCHCYCZDEDKEEESFIFRGBGRHUIEISITLTLUMCNLPLPTROSESISKTR

Effective date: 20061113

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1098372

Country of ref document: HK

17Q First examination report despatched

Effective date: 20071024

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: NOVAGRAAF INTERNATIONAL SA

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20090821

REF Corresponds to:

Ref document number: 602005015686

Country of ref document: DE

Date of ref document: 20090910

Kind code of ref document: P

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2327757

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20090402663

Country of ref document: GR

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E003582

Country of ref document: EE

Effective date: 20091001

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 6184

Country of ref document: SK

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090729

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E006717

Country of ref document: HU

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1098372

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20100503

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: ARROW THERAPEUTICS LIMITED

Free format text: ARROW THERAPEUTICS LIMITED#BRITANNIA HOUSE, 7 TRINITY STREET#LONDON SE1 1DA (GB) -TRANSFER TO- ARROW THERAPEUTICS LIMITED#BRITANNIA HOUSE, 7 TRINITY STREET#LONDON SE1 1DA (GB)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20140312

Year of fee payment: 10

Ref country code: LU

Payment date: 20140326

Year of fee payment: 10

Ref country code: NL

Payment date: 20140308

Year of fee payment: 10

Ref country code: CZ

Payment date: 20140310

Year of fee payment: 10

Ref country code: MC

Payment date: 20140212

Year of fee payment: 10

Ref country code: DK

Payment date: 20140311

Year of fee payment: 10

Ref country code: IS

Payment date: 20140207

Year of fee payment: 10

Ref country code: FI

Payment date: 20140311

Year of fee payment: 10

Ref country code: SK

Payment date: 20140217

Year of fee payment: 10

Ref country code: BG

Payment date: 20140211

Year of fee payment: 10

Ref country code: RO

Payment date: 20140213

Year of fee payment: 10

Ref country code: IE

Payment date: 20140311

Year of fee payment: 10

Ref country code: SE

Payment date: 20140311

Year of fee payment: 10

Ref country code: LT

Payment date: 20140220

Year of fee payment: 10

Ref country code: EE

Payment date: 20140213

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20140213

Year of fee payment: 10

Ref country code: FR

Payment date: 20140311

Year of fee payment: 10

Ref country code: GR

Payment date: 20140214

Year of fee payment: 10

Ref country code: TR

Payment date: 20140227

Year of fee payment: 10

Ref country code: HU

Payment date: 20140225

Year of fee payment: 10

Ref country code: AT

Payment date: 20140226

Year of fee payment: 10

Ref country code: IT

Payment date: 20140318

Year of fee payment: 10

Ref country code: ES

Payment date: 20140211

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20140318

Year of fee payment: 10

Ref country code: GB

Payment date: 20140312

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20140312

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20140417

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20140227

Year of fee payment: 10

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20150918

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005015686

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20150331

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20150318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150918

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 437643

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150318

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E003582

Country of ref document: EE

Effective date: 20150331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20150318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20150401

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 6184

Country of ref document: SK

Effective date: 20150318

REG Reference to a national code

Ref country code: GR

Ref legal event code: ML

Ref document number: 20090402663

Country of ref document: GR

Effective date: 20151002

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20151130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151002

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20151001

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20151001

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20160602

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150319

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150318